The definition of the syndrome shifted from clinical and familial criteria to molecular criteria after Malkin et al 17 and Srivastava et al 18 described the involvement of germline p53 mutations. The mutations initially found were all missense mutations of exon 7, but further studies, extensively reported by Varley et al 19 showed that other regions might also be involved. Studies on series of families with the classical LFS criteria showed that 50 to 70% of these families displayed a p53 mutation, [19] [20] [21] [22] [23] indicating that mutation screening may have overlooked alterations that aVect regulatory regions and not p53 coding sequences or that germline mutation of other gene(s) may be responsible for LFS. Indeed, the study recently published by Bell et al 24 showed that heterozygous germline mutations in hCHK2 occur in LFS. The proportions of p53 mutations are somewhat lower when less stringent criteria are applied. 20 21 After ascribing LFS to germline p53 mutations, diVerent studies were conducted on series of patients with tumours typifying LFS, but not selected on family history, to determine the proportion of gene carriers among them. The studies on patients with bone sarcoma or STS [25] [26] [27] [28] [29] showed that up to a third of the group with early onset, an unusual family history, or multiple primary tumours may be carriers. Children with adrenocortical carcinoma were found to have the highest rate (50-80%). 30 31 The frequency of mutations among patients with multiple primary tumours was estimated to be between 7 and 20%. [32] [33] [34] Far lower rates were found for patients with brain tumours, [35] [36] [37] [38] [39] or early onset/familial breast cancer, [40] [41] [42] [43] although the breast cancer risk was clearly high in p53 mutation carriers. In some of these studies, a selection bias on family history may be suspected. Indeed, a significant proportion of mutations were found among cases with a strong positive family history, the frequency of which appeared to be unusually high.
None of these studies allowed an estimation of cancer risk in mutation carriers, although unaVected carrier relatives are found in family studies. Indeed, LFS selection criteria are so stringent that it is impossible to correct for selection bias. Even looser criteria, such as Li-Fraumenilike 21 44 (LFL) or Li-Fraumeni incomplete 20 (LFI) do not allow correction for ascertainment bias. This was the reason that we undertook a study at the Institut Gustave Roussy with very loose criteria which oVered two advantages: (1) they did not imply the existence of highly penetrant susceptibility genes and therefore potentially allowed the detection of mutations associated with a low cancer risk; (2) correction for selection bias was possible for the estimation of cancer risks in individual subjects. Our main conclusions are: (1) that cancer risks are very high, (2) although unaVected carriers may be observed, there is no evidence for the existence of mutations with particularly low penetrance, and (3) the proportion of de novo mutations is probably substantial. 45 While the above mentioned were gradually defining with ever greater accuracy the relationship between constitutional mutations and cancer types and risks, an international multidisciplinary group was trying to establish recommendations for predictive testing. 44 46-50 For such testing, it was essential, as a first step, to evaluate individual and familial criteria to undertake the initial search in a family, in terms of sensitivity and predictive value. We report here the results obtained from our study on childhood cancer at the Institut Gustave Roussy and on a study of breast cancer in very young women performed at the Institut Curie in France.
The family history of cancer in children under 18 years treated for all types of solid malignant tumours in the Department of Paediatric Oncology at the Institut Gustave Roussy in Villejuif (France) was investigated between January 1991 and May 1997. Information was collected through a direct interview with a trained counsellor for families of patients treated in the department during the study period. Information was obtained via a mailed questionnaire and completed in most cases by a telephone interview for patients treated before that period and no longer followed up or who had died. To minimise possible biases owing to genetic and environmental heterogeneity, only white children were included in the study.
Family data were collected through the proband's parents. They included information on each of the proband's first and second degree relatives and first cousins. When necessary, additional family members, previously informed by the proband's parents, were contacted for a telephone interview. Information on relatives included general characteristics (sex, date of birth, malformations, date and cause of death) and the occurrence of any cancer. When cancers had occurred, confirmation of the diagnosis and age at onset were sought in medical and pathology records. Only invasive cancers were considered, excluding non-melanoma skin cancer and in situ carcinoma.
A subgroup of children in whom the frequency of cancer susceptibility genes would be potentially increased was selected on the basis of the occurrence of either of the following criteria: (1) at least one cancer case aVecting a first or second degree relative before the age of 46 (familial cases) or (2) multiple primary cancers in the proband regardless of his/her family history (multiple tumour cases). In the original protocol, the family was also included if cancer had occurred only in first cousins. This criterion had to be removed since it dramatically increased the proportion of chance aggregation in the selected sample.
p53 was genotyped in peripheral lymphocytes isolated from fresh blood samples. Direct sequencing was used for the first set of 100 samples. Genomic DNA was amplified as three fragments including respectively exons 2-4, exons 5-8, and exons 9-11 which were fully sequenced. Genotyping was subsequently carried out with a functional assay in yeast (FASAY), as described by Ishioka et al 51 and modified by Flaman et al 52 when this test became available. Vent DNA polymerase (New England Biolabs) was used to amplify p53 reverse transcripts before transfection in yeast. Yeast colonies carrying a p53 mutant allele were identified either as His-auxotroph or as red colonies. p53 cDNA was extracted from mutant colonies and sequenced. The FASAY has been reported to show over 90% of p53 mutant alleles 52 as does direct sequencing of amplified p53 exon scores in our hands.
Women suVering from invasive breast cancer before 36 years, which was diagnosed between January 1990 and August 1995 and followed up at the Institut Curie, were interviewed about their family history and were requested to give a blood sample for the study of genes involved in breast cancer predisposition. Among the 275 women fulfilling these criteria, 119 were interviewed between January 1993 and August 1995 and 116 gave their informed consent for DNA analysis.
The pedigrees were constructed by taking into account first to third degree relatives of the proband on both parental sides. Information concerning the family history of tumours and age at onset of the tumours was verified when possible in medical and pathology records.
Screening for the presence of mutations was performed by analysis of PCR products from genomic DNA with denaturing gradient gel electrophoresis (DGGE). Exons 4, 5, 6, 7, 8, 9, 10 , and 11 and respective flanking regions were studied 53 (unpublished data). PCR products exhibiting a variant electrophoretic pattern were directly sequenced on both strands. In order to confirm the loss of biological function of missense mutations detected, a functional assay in yeast was performed according to Flaman et al. 52 Any mutation identified was confirmed on a second independent blood sample.
The objectives of defining criteria for recommending p53 mutation screening are triple: (1) to look for a mutation in situations in which it is likely to be found; (2) to miss as few mutations as possible; (3) not to select subjects who are not carriers. The first objective needs a high positive predictive value, which is the probability that a mutation will be found for given criteria. The second objective needs a high sensitivity, which is the probability that the criteria will be fulfilled, given that the mutation is found. The third objective needs a high specificity, which is the probability that a mutation will not be found given that the criteria are not fulfilled. The positive predictive value can be estimated by the proportion of subjects carrying a germline p53 mutation among those tested using given criteria. The estimation of sensitivity and specificity requires reference criteria that would allow the ascertainment of carriers and non-carriers from an unselected population. These parameters therefore cannot really be estimated. However, it is possible to estimate the relative sensitivity by the ratio between the number of mutations detected when given criteria are applied and the number of mutations detected in the whole sample. Besides, since a negative result is of no value at this point, specificity is not particularly interesting. At this point, the importance of wording should be emphasised. The sentence "a mutation will be found" is used instead of "a mutation exists", because this would also depend on the sensitivity of the method used to detect mutations, which is not the subject of the present study. The positive predictive value and the relative sensitivity are estimated in relation to the whole sample when more and more stringent criteria are applied on: (1) the number and age of aVected relatives, (2) the tumour spectrum (probands and relatives), and (3) the existence of multiple primary tumours.
Of the 2691 children eligible for the family study on 1 January 1998, 239 fulfilled the selection criteria and consented to give a blood sample. Among these 239 children, 211 had at least one first or second degree relative aVected by cancer before 46 years of age, 16 had at least two primary malignant tumours, and 12 fulfilled both familial and multiple tumour criteria. Among these cases, 15 mutations were detected, nine in the first group (4.3%), one in the second (a de novo mutation in a child with rhabdomyosarcoma and adrenocortical carcinoma) (6.2%), and five in the third group (4.2%). The complete descriptions of families with mutations are published elsewhere. 45 Among the 223 children (211 + 12) fulfilling the familial criteria, four levels of nested criteria were defined according to the number and tumour type in the aVected relative(s) and are listed in table 1: very loose criteria (223 children), at least one first or second degree relative aVected by any cancer; loose criteria (141 children), the tumour type in the aVected relative(s) is restricted to sarcoma, brain tumours, breast cancer, adrenocortical carcinoma, haematological malignancies, stomach cancer, melanoma, and germ cell tumours, which are the most prevalent tumours described in LFS; stringent criteria (81 children), the tumour spectrum in relative(s) is restricted to unquestioned tumours, that is, sarcomas, brain tumours, breast cancer, and adrenocortical carcinoma (narrow spectrum); very stringent criteria (21 children), a new criterion is added to the previous ones, at least another first or sec- Tumour spectrum in relative(s) restricted to unquestioned tumours, ie sarcomas, brain tumours, breast cancer, and adrenocortical carcinoma (narrow spectrum) Very stringent New criterion added to the previous ones: at least another first or second degree relative aVected by cancer before 46 years or a sarcoma at any age ond degree relative aVected by cancer before 46 years or a sarcoma at any age. Criteria were also defined by stratification on the tumour type in the proband with two levels, a narrow spectrum tumour (102 children) or any tumour.
The results of the combination of criteria for relatives and probands among the 223 familial cases are given in table 2. They show that the positive predictive values for the criterion "any tumour" in the proband are quite low (less than 15%) except in the category "very stringent" criteria in relatives. It is significantly higher when the tumour type in the proband is restricted to the narrow spectrum and attains 23% when stringent criteria are fulfilled among relatives.
The parameters estimated among the 28 (16 + 12) multiple tumour cases (excluding bilateral tumours of paired organs) are shown in table 3. The positive predictive values are much higher than in the group selected on a familial basis. However, this criterion overlaps markedly with the previous ones; in the six carriers of a germline mutation, five fulfil the "narrow spectrum" for the first tumour of the proband, of which four also fulfil the "stringent" criteria on relatives. Thus, adding the criterion "multiple tumours" in the proband to the combination of narrow spectrum in the proband's tumour and stringent criteria for relatives yields 24 new cases, two of which have a germline mutation. This results in an increase in relative sensitivity from 73% (11/15) to 87% (13/15) and a decrease in the predictive value from 23% (11/47) to 18% (13/71). If both tumours (or at least two tumours) are restricted to the narrow spectrum, then only six families are added, one of which carries a mutation, resulting in a relative sensitivity of 80% (12/15) and a predictive value of 23% (12/53). There are very few multiple tumours among relatives (excluding bilateral tumours of paired organs): six families among which three fulfil the stringent criteria in relatives and four fulfil the narrow spectrum in the proband. There are two p53 mutations, two of which belong to the group defined by narrow spectrum and multiple tumours in the proband and stringent criteria in relatives. Consequently, the predictive value and the relative sensitivity are not modified when multiple tumours are added to the narrow LFS spectrum in relatives (data not shown).
Among the 116 breast cancer cases fully analysed, a total of three germline p53 mutations (2.5%) were detected. Two of them are missense mutations (Leu130Phe, Arg175Gly) and one is an in frame deletion (GluAla346del3Asp). The deleterious eVects of both missense mutations have been confirmed with FASAY. One mutation (Leu130Phe) was found in a woman who was aVected at 31 years and had no family history of cancer and in particular five unaVected sisters aged from 34 to 49 years. The second mutation (GluAla346del3Asp) concerned a case of bilateral breast carcinoma at 29 and 30 years whose family history was clearly indicative of Li-Fraumeni syndrome, including chondrosarcoma at 16 years, leukaemia at 26 years, breast cancer at 20 years, and renal tumour at 36 years (unconfirmed) in the sibship, and the father aVected with a soft tissue tumour of an unknown histological nature at 64 years. The third mutation (Arg175Gly) was detected in a woman suVering from osteosarcoma at 18 years and bilateral breast cancer at 27 and 29 years. Her father had developed a rectal carcinoma at 39 years, meningioma at 54 years, and pancreatic carcinoma at 55 years, and her paternal uncle had developed a germ cell tumour at 45 years.
Because of the small number of mutations found, we had to consider a smaller number of criteria than in the previous section, and only two levels of nested criteria were defined: loose criteria, at least one first or second degree relative aVected by any cancer before 46 years of age or a proband with multiple primary malignant tumours; stringent criteria, the tumour spectrum in relative(s) (or in the proband in case of multiple tumours) is restricted to the narrow spectrum. However, since breast cancer is common in the general population, familial aggregation of breast cancers may be either because of chance or germline BRCA1/2 mutations. Therefore, two situations were considered, the narrow spectrum tumour is breast cancer (situation A) or another tumour (situation B).
Thirty three cases fulfilled the loose criteria (two mutations), 21 cases the stringent criteria A (no mutation), and two the stringent criteria B (two mutations). The positive predictive values are presented in table 4, but not the relative sensitivities which would be meaningless with only three mutations.
Most of the studies on germline p53 mutations conducted to date and quoted in the introduction did not permit evaluation of diVerent selection criteria. Some of them concerned families ascertained on the basis of strong familial aggregation (corresponding roughly to our very stringent criteria) and the relevance of looser criteria could not be assessed. Other studies concerned series of tumours with very limited information on family history, so that it was impossible to evaluate criteria. The most well documented studies are by the group of Jillian Birch, based on the Manchester Children's Tumour Registry. 16 21 These authors showed the relatively high predictive value (4/18=22%) of the so called Li-Fraumeni-like criteria, that is, a proband with any childhood cancer or sarcoma, brain tumour, or adrenal cortical tumour diagnosed under the age of 45 years with one first or second degree relative with a typical LFS cancer at any age, plus a first or second degree relative in the same lineage with any cancer under the age of 60 years. There is some degree of overlap between these criteria and ours; 18 families conform to this definition in our sample, four of which exhibit a p53 mutation, which is exactly the same number and proportions as those found by these authors. Note that all positive families fulfil our stringent criteria in relatives and narrow spectrum tumour in the proband.
In the present study, we have quantified various criteria which can be a very useful basis for establishing recommendations for conducting p53 screening.
The functional assay used in the study on childhood cancer detects about 90% of mutations in p53. 52 Mutations in exons 2 and 3 are very rare and were not studied in the study on breast cancer A small number of mutations may thus have been missed and the positive predictive value of criteria may thus be slightly higher, which should not modify our conclusions.
At present, searching for p53 germline mutations is still a cumbersome task and laboratories which perform such screening in France are in favour of criteria yielding a positive predictive value of at least 20%. In our study on childhood cancer, this value is achieved when the following criteria are used: a proband with a narrow spectrum tumour and at least one first or second degree relative aVected before 46 years by a narrow spectrum cancer or multiple primary tumours or a proband aVected by multiple primary tumours whatever the family history. It should be noted that when very stringent criteria are used, that is, that are very close to those used in previous studies to define LFS, very similar results are obtained with a positive predictive value of 53%.
For cancer occurring in adulthood, our data concern only very early onset breast cancer, which is the most frequent tumour in p53 carriers (80% of tumours occurring among female carriers after 16 years of age 45 ). As it is also common in the general population, we have presented the results separately when breast cancer is the narrow spectrum tumour in the relative who was the determinant factor in the inclusion of the family (criterion A) and when it is another cancer (criterion B). Although this distinction results in loss of precision of estimations owing to a decrease in sample size, it should be noted that no mutation among 21 cases was detected when criterion A was found, whereas both cases with criterion B were p53 carriers (p=0.02, exact test). Consequently, as in childhood cancer, it seems reasonable to use stringent criteria and to add this restriction on tumour type, that is, exclude breast cancer from the tumour spectrum in relatives.
Although the results obtained by ascertaining early onset breast cancer probands cannot necessarily be extrapolated to all tumours of the narrow spectrum, we expect that the predictive value for the other tumours will be higher than that obtained for breast cancer, given the high frequency of this tumour in the population.
In addition, although we have very few data on adrenocortical carcinoma not selected on family history, it seems logical to add this criterion considering the results of published studies quoted in the introduction.
Finally, it should be noted that although leukaemia is usually reported as belonging to the LFS, this was not included among narrow spectrum tumours in the present study for two reasons. (1) It is absent in our childhood probands because the Department of Paediatrics at the Institut Gustave Roussy treats only solid tumours. (2) Leukaemia is frequent in the general population and the inclusion of families with one relative aVected by this cancer would dramatically increase the probability of chance aggregation.
With our knowledge of the interest of the criteria evaluated in this study and considering the state of the art for p53 mutation screening, the French LFS group decided to recommend a search for p53 mutation in families fulfilling the following criteria: (1) a proband aVected by a narrow spectrum cancer before 36 years and at least one first or second degree relative aVected by a narrow spectrum tumour (other than breast cancer if the proband is aVected by breast cancer) before 46 years or multiple primary tumours; (2) a proband with multiple primary tumours two of which belong to the narrow spectrum and the first of which occurred before 36 years, whatever the family history; (3) a proband with adrenocortical carcinoma whatever the age of onset and family history. Using such criteria, we expect to find a mutation in about 20% of cases and to miss about 20% (3/15) of the mutations which would be detected using the loosest criteria. These criteria could of course be modified in the near future with more eYcient laboratory detection methods and re-evaluated prospectively.
Identification of a transcriptionally compromised allele of c-MYC in a North American family EDITOR-Chromosomal translocations that target c-MYC at 8q24 are found in all Burkitt's lymphomas (BL), AIDS related non-Hodgkin's lymphoma (AIDS-NHL), mouse plasmacytomas (PCTs), in many examples of diVuse large cell lymphoma (DLCL), and in multiple myeloma (MM). Indications are that c-MYC is under strict control and when deregulated results in unchecked cellular proliferation and hyperplasia. Non-random chromosomal translocations found such as t (8;14) , t(8;22), or t(2;8) in these lymphoid neoplasias places c-MYC under the control of strong immunoglobulin enhancers, which leads to overexpression. 1 2 In addition, c-MYC is amplified in many tumours including breast, prostate, gastrointestinal, ovarian, MM, myeloid leukaemia, and melanoma suggesting that the overall transcriptional level is probably a key transforming element associated with c-MYC. 3 Besides genetic lesions, other epigenetic factors such as activation of growth factor receptors may also lead to constitutive expression of c-MYC. Thus, considerable eVorts have been made systematically to identify the c-MYC transcriptional apparatus (promoters and enhancers) in an eVort to control c-MYC expression. While c-MYC transcription potentially initiates from one of three promoters, P0, P1, and P2 which reside in the exon 1 region, the P2 promoter normally accounts for 75-90% of cytoplasmic c-MYC RNAs. To date, more than 20 transcription factors have been found to reside in the proximity of exon 1 of c-MYC. 1 Actually, c-MYC was one of the first genes to exhibit transcriptional blockage. RNA polymerase II initiation complexes were shown to pause on P2 before activation. [4] [5] [6] Upon chromosomal translocation, the insertion of IG enhancer elements renders a shift in promoter usage from P2 towards P1 and loss of transcriptional blockage. 7 In concert with the intensely regulated transcriptional machinery, the sequences surrounding c-MYC appear to be strictly conserved across species boundaries and little in the way of sequence variation or allelic polymorphisms has been identified. In fact, attempts to position c-MYC in the mouse by genetic recombination techniques were ultimately achieved only when wild mice were backcrossed to inbred mice. 8 Recently, we and others 9 have identified several alleles of human c-MYC (S11N, CAA-33) through single nucleotide polymorphism (SNP) analysis of the coding region among a large random panel of normal healthy subjects of African-American and white descent. 10 Comparisons of the S11N and CAA-33 alleles to wild type alleles at the RNA level showed that the CAA-33 allele is transcribed less eYciently in peripheral blood leucocytes. Although the nature of this diVerence remains to be elucidated, the finding that CAA-33 is transcriptionally compromised and is found almost exclusively in people of African descent underlines the importance of the genetic background in studies on the control of c-MYC expression. Thus, studies of allelic diVerences and transcription of human c-MYC will provide useful paradigms in the attempt to control or regulate c-MYC expression in normal and disease conditions.
We have considered the possibility that sequence diVerences that exist in the coding region of c-MYC could result in feedback inhibition of transcription. For example, somatic point mutations have been found in both BL 11 12 and AIDS-NHL 13 14 to be clustered in c-MYC exon 2 in the region responsible for binding of P107 or other factors to the transactivation domain (TAD). 15 16 This suggests that disruption of binding in this region might lead to a functional inactivation of c-MYC. Indeed, a substitution at residue Thr-58 in the TAD of v-Myc in the avian retroviruses MC29, MH2, and OK10 is known to contribute to the transformation of fibroblasts. 17 While it is believed that a major consequence of somatic mutation in c-MYC could be loss of function, it is not clear which residues are critical.
We wish to report the discovery of a unique sequence (S288K AGC→AAC) in the coding region of c-MYC which we have recently found in a North American family (fig 1) . The S288K substitution resides just distal to the acidic domain and proximal to the nuclear localisation signal and was detected by PCR amplification and sequencing of the exon 3 region of human c-MYC. Subsequently, we developed a single stranded conformational polymorphism (SSCP) assay for S288K which we have used to survey panels of normal, healthy, white (around 200), AfricanAmerican (around 200), Hispanic (two) and Asian-Pacific (two) subjects. We were unable to find further evidence of the S288K allele among these subjects or among disease panels of AIDS-NHL (around 200), BL (around 40), MM (around 20), small cell lung carcinoma (around 25), or neuroblastoma/neurocytoma (around 60). Thus, S288K appears to be the lowest frequency MYC variant allele identified to date in the North American population. To learn more about the origin of the S288K allele, we obtained peripheral blood samples from the North American family of the proband and we have concluded that the father (No 557) and a daughter (No 554) are heterozygous carriers and present with no apparent phenotypic abnormalities. The family is white with a largely western European background and no apparent predisposition to the development of cancer or other metabolic diseases. We have compared expression of the S288K allele to the wild type allele by SSCP and RT-PCR amplification of RNA made from peripheral blood (fig 1) . We find that S288K is expressed at extremely low levels or not at all in either subject and this result has been confirmed by sequencing individual subclones (13 in total) of RT-PCR amplified RNA from No 554 (a ratio of 12:1 subclones for codon 288 K:S).
We present two hypotheses to explain the compromised expression of S288K in comparison to wild type. The conformational change associated with a serine to lysine change at codon 288 could abrogate binding of a transcription factor and lead to repression of c-MYC. In fact, the transcription factor YY1 which acts to down regulate c-MYC expression through both direct 18 and indirect eVects 19 is known to bind in the proximity of this region. 20 An alternative hypothesis is that S288K carries additional sequence diVerences in the 5' untranslated region which aVect transcription. We cannot distinguish between these alternatives until more detailed cloning and sequencing is accomplished. Nevertheless, S288K represents the second instance of an allele of c-MYC (in addition to CAA-33) in which transcription is less robust in comparison to wild type.
Numerous reports of an L-MYC polymorphism have been linked to disease susceptibility in soft tissue sarcomas, oral cancers, colorectal cancers, NHL, breast carcinoma, and non-SCLC, whereas the same alleles seem to be associated with resistance to hepatocellular carcinoma. 21 22 The reason for this apparent paradox can be attributed to a basic lack of quantitative expression data for L-MYC alleles at the RNA or protein level in tumour versus normal tissue. 3 Understanding gene expression today has progressed from studies of the 5' untranslated/promoter regions to include large constructs of enhancers, matrix attachment regions, locus control regions, and methylation [2] [3] [4] [5] [6] [7] and this dominantly inherited familial cancer syndrome has been designated a hereditary diVuse gastric cancer (HDGC). 4 So far, no germline mutations have been identified in site specific intestinal type gastric cancer. Based on the guidelines of the First Workshop of the International Gastric Cancer Linkage Consortium (IGCLC), the following criteria were introduced: (1) two or more documented cases of diVuse gastric cancer in first/second degree relatives, with at least one diagnosed before the age of 50 or (2) three or more cases of documented diVuse gastric cancer in first/second degree relatives, independently of age of onset. In addition, criteria for familial intestinal gastric cancer (FIGC) were defined. 8 In the present study, we analysed 11 Finnish gastric cancer patients with a family history of disease and two sporadic cases with germline E-cadherin gene mutations (table 1, fig 1) . None of these families completely fulfilled the criteria for other inherited cancer syndromes with predisposition to gastric cancer, for example, hereditary non-polyposis colorectal syndrome (HNPCC), familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, or Li-Fraumeni syndrome (LFS). 8 9 Five of the families studied fulfilled the criteria for HDGC syndrome ( E-cadherin mutation analysis was performed by genomic sequencing of the 16 coding exons including exon/intron boundaries. DNA from one patient with gastric cancer from each of the families was isolated according to standard procedures. Exons were amplified using primers described by Berx et al, 10 except exons 4 and 5, which were amplified as described in Gayther et al. 2 The reactions were carried out in a 50 µl reaction volume containing 100 ng of genomic DNA, PCR buVer (PE/ABI, Foster City, CA), 200 µmol/l each dNTP (Finnzymes, Espoo, Finland), 0.6 µmol/l each primer, and 1 unit AmpliTaq GOLD polymerase (PE/ABI). The concentrations of MgCl 2 in the reaction mixture were as described by Berx et al, 10 except that for exon 6 the concentration of MgCl 2 was 1.5 mmol/l and for exon 1 DMSO (5%) was included in the reaction mixture. PCR reactions were carried out as described in Berx et al group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from with the following changes: annealing temperature for exon 2 was 54°C, for exon 6 56°C, for exon 8 54°C, and for exon 13 57°C. Sequencing reactions containing 40 ng of the PCR product with 3.2 pmol of the sequencing primer in a volume of 12 µl were performed using ABI Prism Dye Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer, Foster City, CA) or ABI Big Dye Terminator Kit (Perkin-Elmer, Foster City, CA) according to the manufacturer's instructions. Sequencing reactions were electrophoresed either on 6% Long Ranger gels, containing 8 mol/l urea, or 5% Long Ranger gels, containing 6 mol/l urea, and analysed on an Applied Biosystems model 373A or 377 automated DNA sequencers, respectively.
Exons 1 and 4 were amplified as described above and analysed using SSCP from 84 and 212 cancer free controls, respectively. After PCR, 5 µl of each sample was mixed with 5 µl of denaturing loading buVer (95% formamide, 20 mmol/l EDTA, 0.05% bromphenol blue, 0.05% xylene cyanole FF), denaturated for five minutes at 94°C and loaded into a 0.4 mm × 30 cm × 45 cm gel. Electrophoresis was performed for exon 1 using gels containing 0.5 × MDE solution (AT Biochem, Malvern, PA) and 0.6 × TBE buVer and were run at 4 W for 20 hours. Exon 4 was analysed using 1 × MDE solution and 2.5 mol/l urea at 6 W for 14.5 hours. The gels were silver stained according to standard procedures.
We detected one potential missense mutation in the coding E-cadherin gene sequence (table 1, fig 1, No 1) . A C to G change occurred in codon 172 in exon 4 resulting in substitution of proline by arginine (P172R) (fig 2A) . This family contains seven gastric cancer cases in three diVerent generations. Three of the aVected subjects had gastric cancer under 50 years of age (33, 39 , and 40 years). One of them also had ductal breast cancer. In addition, one patient with both bladder and ovarian cancer and another with prostate cancer and basalioma were found in this family. To investigate the segregation of this missense type change in the family, we screened two additional family members with gastric cancer (fig 1) . DNA from paraYn embedded tissues was isolated according to standard procedures and mutation analysis was performed as described above. However, neither of them carried the P172R change. One of the patients studied was the mother of the mutation carrier. The father of this patient died at the age of 94 years and was cancer free. This change was also absent in 212 control samples from cancer free subjects, as screened by SSCP analysis ( fig 2B) . The change appears to be a rare polymorphism.
Four additional polymorphisms of the E-cadherin gene were found in this series of gastric cancer patients. A C to T silent change in codon 692 (from alanine to alanine) occurred in eight of 13 (61.5%) gastric cancer patients. A C to T change in codon 751, resulting in aspartate substitution by asparagine, was detected in three of 13 (23%) patients. These two polymorphisms have been previously reported. 10 11 A C to G change was found before the start codon (−71 bp) in the non-coding region in one of 13 (7.7%) gastric cancer patients and in two of 51 (3.9%) cancer free controls. A T to C change at position +6 in intron 1 occurred in five of 13 (38%) gastric cancer patients and in 18 of 51 (35%) cancer free controls.
So far, altogether 14 truncating E-cadherin germline mutations have been detected in gastric cancer patients. 8 A few putative missense germline mutations have been reported but their functional significance has not been tested. 1 6 7 In the sporadic type of cancer there seems to be a cluster of mutations between exons 7 and 9 whereas germline mutations are more evenly distributed. 8 11 A novel missense type change, P172R, found in this study is located in exon 4 which encodes a large extracellular domain with Ca 2+ binding motifs (exons 4-13). 10 Based on the segregation of the mutation in aVected cases in this particular family, it seems that this change is not a pathogenic mutation. It seems to be a very rare polymorphism because none of the 212 cancer free controls carries this change. This finding is interesting because altogether seven gastric cancer cases were found in this family. Caldas et al 8 have suggested that E-cadherin should account for 25% of the families fulfilling the established criteria for HDGC. However, PCR based screening methods used in this study do not allow detection of all mutation types, for example, large deletions.
Our results support the notion that germline mutations in the E-cadherin gene are responsible for only a subset of gastric cancer patients with a family history of the disease. In our study, no mutations were found in 13 gastric cancer probands. Five of the families studied fulfil the criteria for HDGC and one for FIGC. Our data suggest that for the purpose of eYcient E-cadherin mutation detection, there may be a need for more stringent criteria for HDGC, such as requiring three aVected subjects as is common in research on familial breast and colon cancer. However, our data set is limited. Loose inclusion criteria should encourage collection of gastric cancer families. This is important, because further work is necessary to identify predisposing gene(s) for a subset of HDGC families, as well as families segregating intestinal gastric cancer. 
Figure 2 (A) Direct sequencing shows a heterozygous C→G change (P172R, see arrow). (B) SSCP analysis of the P172R change. A positive control (lane 4) was included in all SSCP runs.
ATT TC CTAAA The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome EDITOR-Bannayan-Riley-Ruvalcaba syndrome (BRRS) is an autosomal dominant condition which includes the features of macrocephaly, hyperpigmented penile macules, and hamartomatous tumours, including lipomas, haemangiomas, and gastrointestinal polyps. [1] [2] [3] [4] In 1996, it was recognised that BRRS shared features with Cowden syndrome, another autosomal dominant condition with multiple hamartomas. 5 Cowden syndrome is characterised by trichilemmomas (small, benign hair follicle tumours), oral papillomas, intestinal polyps, and increased frequency of breast and thyroid cancers in aVected subjects. 6 Germline mutations in the PTEN gene (phosphatase and tensin homologue deleted on chromosome 10), a gene associated with somatic deletion in a number of cancer cell lines and some primary tumours, were identified in families with Cowden disease the following year. [7] [8] [9] [10] At the same time, mutations in the PTEN gene were identified in several BRRS families, 11 providing evidence that these conditions are allelic. Identical mutations have been identified in some families with Cowden syndrome and in others with BRRS. 12 In addition, families whose members have overlapping features of both conditions have been identified. 13 14 However, publications on BRRS provide little clinical information on the natural history and progression of this condition. Here we review our experience following 10 subjects in three families with BRRS and PTEN mutations. The criteria for ascertainment were at least one aVected person in a family with at least two of the three features of macrocephaly, hamartomas (including at least one lipoma, haemangioma, or intestinal polyp), and penile macules in males. AVected subjects were found to have germline PTEN mutations by DNA analysis. 12 13 15 The pedigrees of the families are presented in fig 1 and their clinical features are summarised in table 1.
Family 1 is of Native American descent and has been followed for six years ( fig 1A) . The father and four of his five children are aVected. The proband, III.2, was born at 37 weeks' gestation after an uneventful pregnancy with birth length and OFC between the 90th and 97th centiles. He has been a healthy child but had markedly delayed cognitive development. He sat at 8 months, walked at 16 months, and had only one word at 4 years of age. He has exhibited autistic behaviour consisting of arm flapping, head banging, and repetitive and self-stimulatory mannerisms. Hyperpigmented macules of the penile shaft were first detected at the age of 7 years 3 months. They had not been present at 4 1 ⁄2 years during a previous evaluation when the diagnosis of BRRS had been considered based on the presence of macrocephaly, developmental delay, and a lipoma on the back. Laboratory evaluations included fragile X testing and karyotype analysis, both of which were normal. At his most recent evaluation, at the age of 8 years 10 months, he had height and weight measurements on the 95th centile. His OFC was 58.8 cm, on the 98th centile for an adult male. He had obvious mental retardation, with very few words and markedly autistic behaviour. His palpebral fissures were downward slanting.
The proband's older sister, III.1 in family 1, was 5 years 9 months old at the time this family was first seen. She was born at ∼37 weeks' gestation after an uncomplicated pregnancy with birth weight 4000 g (>97th centile) and length 50.8 cm (97th centile). She had an isolated, small, left groin lipoma at the initial evaluation. She sat at 7 months, walked at 15 months, and exhibited delayed speech although to a much lesser degree than her brother. At her most recent evaluation at the age of 9 years 10 months, her height was between the 75th and 90th centiles, her weight was on the 75th centile, and her OFC was 57 cm, just less than the 98th centile for an adult female. She had downward slanting palpebral fissures, joint hypermobility, and a high arched palate.
III.3 in family 1 was first evaluated at 3 years. Her birth history was unavailable. She walked at 18 months and used a few single words at 3 years. When last evaluated, at the age of 7 years 1 month, she had height on the 95th centile, weight greater than the 95th centile, and head circumference of 58 cm, greater than the 98th centile for an adult female. She exhibited mild mental retardation, most notably speech delay, and had joint hypermobility and a high arched palate, but did not have any cutaneous manifestations of BRRS.
III.4 in family 1 ( fig 2A) was born at 37 weeks' gestation after an uncomplicated pregnancy with a birth weight of 3490 g. Other birth parameters were unavailable. He walked at 21 months and had three to four words at his first genetic evaluation at 22 months of age. At his next evaluation, aged 4 years 3 months, he had two small hyperpigmented macules involving the penis. He developed seizures related to hypoglycaemia at the age of 12 months, and had an extensive metabolic workup that was not informative. Normal laboratory studies have included electrolytes, thyroid function tests, insulin, growth hormone, cortisol, lactate, carnitine (urine and plasma), urine organic acids, and plasma amino acids. He has a history of ketonuria associated with hypoglycaemia. A muscle biopsy was normal, without evidence of lipid myopathy, although the muscle carnitine levels were somewhat low and he is being treated with oral carnitine. A cranial MRI performed at 3 years 8 months and repeated two years later showed normal ventricles and patchy increased T2 signal in the deep and subcortical white matter of both occipital lobes with prominent perivascular spaces. His EEG was abnormal, with diVuse slowing and epileptiform discharges over both occipital lobes. When last evaluated at the age of 7 years 2 months, he had height and weight both above the 95th centile and an OFC of 58.2 cm (98th centile for an adult male). He had four visible macules on the shaft of the penis. His back was hirsute. He continued to exhibit global developmental delay and had joint hypermobility and a high arched palate.
The proband's father, II.5 in family 1, has had learning diYculties and macrocephaly ( fig 2B) . He was reportedly a large infant. He has multiple hyperpigmented macules on his penis. At the age of 28, he had a thyroidectomy for goitre. Pathological examination showed adenomatous nodular hyperplasia without evidence of carcinoma. At the last evaluation aged 29 years, his height was on the 50th centile, weight was just greater than the 95th centile, and OFC was 64.2 cm, much greater than the 98th centile. He was hirsute and had a high arched palate.
III.5, the youngest child in family 1, is normocephalic, without hamartomas or penile macules. When last evaluated at the age of 3 years 9 months, his height and weight were between the 75th and 90th centiles and his OFC was 52 cm (80th centile). He had mild joint hypermobility and a normal palate. He has had normal development. In this family, there has not been any documented breast or thyroid cancer, nor gastrointestinal polyps, although formal endoscopy has not been performed. The father's sibs and parents were unavailable for evaluation.
Family 2 is of Dutch and other European extraction ( fig  1B) . The proband, III.1, has been followed for three years. He was initially evaluated for macrocephaly, speech delay, and a family history of Cowden syndrome. Born at term, his birth weight was on the 90th centile and birth length was between the 10th and 50th centiles. Because of a large head and a birthmark along the spine, he had a head CT scan which showed megalencephaly without hydrocephalus, and an MRI of the lumbar spine was normal. When evaluated at the age of 10 months, he had normal development, macrocephaly, and a lipomatous vascular malformation in the lumbar spine region. When evaluated at 3 years 2 months, he had a broad forehead, a fleshy vascular mal- group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from formation measuring ∼3 × 4 cm, located above the gluteal cleft (fig 3) , and several small café au lait macules. He had delayed motor development, and had a vocabulary of only five to ten words. There were no hyperpigmented penile macules. Normal laboratory studies included thyroid profile, growth hormone levels, and karyotype. A cranial MRI at 3 years 9 months showed a small left frontal venous malformation and evidence of mild prominence of the perivascular spaces. At 3 years 10 months, his height and weight were above the 95th centiles, with an OFC of 59 cm (>98th centile for an adult male). There were no penile macules.
II.5 in family 2, the proband's father, has had macrocephaly, multiple lipomas, and learning problems. His birth weight was between the 10th and 50th centiles and the delivery was complicated owing to large head size. At the age of 11 years 11 months, he was documented to have an OFC of 60.2 cm (>98th centile for an adult male), with weight on the 75th and height on the 90th centiles. He had undergone several surgical resections of subcutaneous lipomas. A head CT scan was normal. He exhibited delayed motor and cognitive skills with intelligence in the borderline range (IQ 77-79). He developed a goitre in his teenage years and underwent thyroidectomy at the age of 26 for papillary carcinoma. He was later found to have benign polyposis during evaluation for gastrointestinal complaints. Based on the presence of facial skin papules, he was tentatively given the diagnosis of Cowden syndrome, although the biopsy was not confirmatory for trichilemmomas. We have no information regarding penile macules because he was not examined for this finding and is unavailable for evaluation.
Other contributory history for family 2 is a report of gastrointestinal polyps in I.1, the proband's paternal grandfather. He did not have thyroid or learning problems.
Family 3 is of predominantly European extraction and has been followed in the genetics clinic for three years ( fig  1C) . The proband, III.1 ( fig 4A, B) , was born at 36 weeks' gestation by caesarean section for fetal macrocephaly with birth weight 3630 g (97th centile). At the age of 4 months, his OFC measured 45 cm (>98th centile) with weight and height on the 25th centile. He had a generalised seizure disorder, with normal EEG and MRI as an infant (except for macrocephaly), episodic ketotic hypoglycaemia, and a history of hypotonia. Motor milestones were moderately delayed with crawling at 17 months and walking at 18 months, and he had language impairment with more severe expressive than receptive delays. When first evaluated in the genetics clinic aged 2 years 4 months, he was noted to have macrocephaly with mild frontal bossing but no dysmorphic facial features. His skin examination was notable for three café au lait macules on his trunk, only one measuring greater than 0.5 cm in diameter, as well as a left preauricular telangiectasia from an involuted capillary haemangioma. No lipomas or penile macules were identified. At his most recent evaluation, aged 5 years 2 months, his height was between the 50th and 75th centiles, weight between the 90th and 95th centiles, and OFC measured 60.2 cm (>98th centile for an adult male). Other findings included a high arched palate, joint hypermobility, and broad thumbs and big toes, but no penile hyperpigmentation. He had speech articulation problems. A karyotype study was normal.
The proband's maternal half brother, III.2 in family 3 ( fig 4A, B) , whose father is of probable African-American extraction, was born at 37.5 weeks' gestation by repeat caesarean section. Prenatally detected macrocephaly prompted amniocentesis, which showed a normal karyotype. Birth weight was 3940 g (97th centile) and length was 53.5 cm (just greater than the 97th centile). OFC was not available. He had a normal newborn course but was evaluated at 6 months for hypotonia and motor delay. At 7 1 ⁄2 months, he was noted to have height and weight on the 50th centile but OFC measuring 51 cm (>98th centile). During genetic evaluation at 10 months, he had macrocephaly, frontal bossing, midface hypoplasia, hypotonia, and joint laxity. DiVuse hyperpigmentation of the penis was 
Figure 2 Features of BRRS in family 1. (A) Macrocephaly but otherwise normal cranial configuration of III.4. (B) The father (II.5) also has macrocephaly.
noted. At his most recent evaluation, at 3 years 7 months, his growth parameters included height on the 50th-75th centile, weight on the 90th centile, and OFC of 59.8 cm (>98th for adult male). Four discrete hyperpigmented macules were identified on the penile shaft and two on the scrotum. He had mild hypotonia and joint hypermobility, as well as a high arched palate. In spite of mild motor delay, he has had normal language acquisition and has not qualified for special education programmes. The biological mother of the two boys (II.6 in family 3) has not been available for evaluation and has not been their caregiver owing to concerns of neglect. She is reported to have an OFC of 63 cm (much greater than the 98th centile for an adult female) and a history of childhood seizures, hypoglycaemic episodes, and developmental disabilities. Of her four full brothers, two are reported to have macrocephaly, one with hydrocephalus and an Arnold-Chiari malformation (II.3). The proband's maternal grandfather (I.1) reportedly had macrocephaly and diabetes and died aged 36 in a car accident. There are no reports of breast or thyroid cancer or gastrointestinal polyps in this family, although endoscopy has not been performed.
Molecular analysis was performed on genomic DNA extracted from peripheral blood leucocytes as previously described. 12 15 In family 1, a germline heterozygous nonsense mutation in the PTEN gene was identified at codon 130 leading to premature termination of the protein (R130X) within the highly conserved phosphatase domain. The father and four aVected children carried the R130X mutation, which was not present in the youngest unaVected child, III.5. In family 2, blood was obtained for PTEN mutational analysis on the proband and his unaVected mother, and a mutation was identified in the proband at position 5 in intron 6 (IVS6+5G→T). His mother did not share this allele. In family 3, only the proband and his half brother were available for testing. A mutation in the PTEN gene at position 5 in intron 6 (IVS6+5G→A) was detected in one allele from each of the two boys. This specific mutation has not been previously described. The mutations in families 2 and 3 are likely to lead to aberrant RNA splicing and a truncated protein product.
In identifying our families with BRRS, we focused on subjects possessing at least two of the three features of group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from macrocephaly, hamartomas, and penile macules, criteria which have been used to ascertain BRRS patients for molecular studies. 11 13 It has been suggested that the mere presence of macrocephaly/macrosomia and developmental delay, without hamartomata or penile macules, should warrant further evaluation for PTEN mutations. 16 In fact, macrocephaly has been the most consistent finding in BRRS in numerous reviews [17] [18] [19] and was present in all of our aVected subjects. The macrocephaly consists of megalencephaly without ventricular dilatation and is generally present at birth. 20 We were surprised by the degree of macrocephaly in all aVected members of family 1, with head circumference measurements greater than the 98th centile for age, in the absence of facial dysmorphism or other distinguishing cranial features such as frontal bossing. Presumably, the overall large body size masked the disproportionately large head size in these subjects. Families 2 and 3 also exhibited marked macrocephaly, and the aVected children had a broad, prominent forehead that has been previously described in BRRS. 21 The broad spectrum of hamartomata is illustrated by these families. Although family 1 was first brought to medical attention because of familial macrocephaly and developmental delay, the diagnosis of BRRS was not suspected until single lipomas were identified in two of the four aVected children. As the children have grown, these lipomas have become less visible. None of the members in family 1 has been evaluated for gastrointestinal polyposis and symptoms such as intestinal bleeding or chronic abdominal pain have not been reported. The father in family 2 had several classical tumours of BRRS, including multiple lipomas evident by his teens and intestinal polyps. His young son had only a vascular malformation along the lumbar spine. In contrast, the aVected boys in family 3 have had no obvious hamartomata. These cases illustrate the importance of a thorough skin examination at each evaluation of a child with macrocephaly, although the absence of dermatological abnormalities does not exclude the diagnosis.
Penile macules are perhaps the most distinctive and potentially valuable diagnostic feature of this syndrome. This is shown by family 1, in which penile macules were important in establishing the diagnosis and were not identified in the oldest son (III.2) at the age of 4 1 ⁄2 years but were seen at 7 years 3 months. His younger brother had two very small hyperpigmented macules identified at the age of 4 1 ⁄2 years and four small penile macules by 7 years 2 months. Only one of the two aVected half brothers in family 3 had penile macules, which were first visualised between the ages of 2 1 ⁄2 and 3 1 ⁄2 years, although generalised penile hyperpigmentation was seen in infancy. He is of mixed racial heritage, with an African-American father, which may increase the likelihood of pigmentation, since his fully white older brother with the identical mutation did not have penile macules. The penile macules detected in all of the children were very small pigmentary changes that might be missed during a cursory examination and were far less obvious than many published photographs. 5 18 We conclude that speckling of the penis is more likely to occur in later childhood, and its absence in infants and toddlers should not exclude consideration of the diagnosis of BRRS.
Mental retardation has been a feature in case reports of BRRS 22 and has been reported in 15-20% of aVected subjects in two previous surveys. 17 20 More common are motor and speech delays occurring in childhood in approximately 50% of patients. These delays are reported to improve with age in many cases, 18 and adults are often described as having motor dysfunction with normal IQ. 20 In our families, all aVected subjects had some degree of learning impairment. In family 1, the degree of cognitive disability was highly variable, with the father exhibiting the mildest learning problems. All of his aVected children were in special education programmes, and the two aVected sons had the greatest impairment, with the oldest son at the age of 9 years showing autistic behaviour and minimal expressive language. To our knowledge, autism has not been described previously in this condition. The second family had two aVected males with learning problems; the father had borderline intelligence on repeated testing and his son had significant global delay and behavioural problems. The aVected children in both of these families appeared to have more severe cognitive impairment than their parents, a phenomenon which has been described in other families with BRRS or Cowden syndrome. 14 23 24 In family 3, both children exhibited motor and speech delay, although the oldest son was more severely aVected; their mother was reported to have developmental disabilities as well. The true prevalence of mental retardation in this disorder remains to be established, but for those children suspected of carrying this diagnosis, developmental assessments and appropriate therapeutic interventions are important aspects of care.
Based on the clinical features in these aVected subjects, summarised in table 1, we suggest that some "soft" clinical signs may aid in diagnosis when a young child exhibits macrocephaly and learning delay but may not have developed hamartomata or, if male, penile macules. One of these features is a high arched palate, which has been identified in 56-70% of BRRS patients in other surveys 17 20 25 and was identified in all of our patients. Overgrowth, of either prenatal or postnatal onset, is a feature exhibited by almost 90% of our cohort. Approximately 50% of newborns with BRRS have been reported to have large birth weight and length, with subsequent postnatal growth deceleration resulting in normal growth parameters by adulthood. 18 20 As newborns, five of the patients were macrosomic, with either birth weight or length greater than the 95th centile. Three of the aVected children in family 1 have exhibited postnatal overgrowth, as has the aVected boy in family 2. The father and oldest daughter in family 1 now have normal height and weight, suggesting that the overgrowth resolves by adulthood and perhaps puberty. Since the disturbance in growth velocity appears to be age dependent, it may not be appreciated without following growth curves over time. Other findings with greater than 50% incidence in our cohort include joint hypermobility and hypotonia. Hyperextensibility of joints has been reported in approximately 50% of patients with BRRS, 17 20 25 and hypotonia in approximately 20%. 17 20 These reports also identified downward slanting palpebral fissures in a majority of their patients, a finding which was less common in our cohort. Frontal bossing, hypoglycaemic episodes, seizures, and café au lait macules were all identified in approximately 1/3 of our patients. The presence of these less specific findings may support the diagnosis of BRRS.
It has been suggested that BRRS shows a male preponderance, and that this reflects the overall increased incidence of macrocephaly in males. 19 26 In previous surveys, even before the recognition of penile macules as a clinical feature of the disorder, ∼70% of identified patients were male. 17 20 In our three families, seven out of 10 subjects at risk for BRRS were male, with six of these males mutation positive. However, both at risk females in family 1 were also aVected, so we do not have adequate numbers to draw conclusions regarding this male preponderance. Since our inclusion of penile macules as a diagnostic criterion may lead to bias in recognising males with this disorder, further studies incorporating mutation analysis are warranted to confirm the observation that more males are aVected with BRRS. The opposite sex ratio may exist for Cowden syndrome, which has been reported to exhibit a female preponderance. 24 27 However, breast cancer is much more prevalent in females in general, and women may be more likely to report facial papules because of cosmetic concerns, so females with Cowden syndrome may be more readily identified than aVected males. As a consequence of these sex specific clinical features, the reported ratios in each disorder may merely reflect ascertainment bias.
PTEN mutations have now been identified in up to 80% of patients with Cowden syndrome and in up to 60% of those with BRRS, indicating that they are allelic disorders. 7 12 13 15 In several cases, the same PTEN mutation has been identified in families with a diagnosis of either Cowden syndrome or BRRS, and in other cases family members carrying the same PTEN mutation have diVerent diagnoses. 13 14 23 There is significant overlap between Cowden syndrome and BRRS, and two of the features found in both conditions are macrocephaly and thyroid abnormalities. 5 6 18 The father in family 1 had thyroidectomy for adenomatous nodular changes although he and his children fit the description of BRRS better than Cowden syndrome. Family 2 also illustrates the overlap in phenotypic features of these conditions. The son had the BRRS findings of macrocephaly, a haemangioma, and developmental delay, while his father had macrocephaly, borderline intelligence, and features more consistent with Cowden syndrome, including GI polyposis, thyroid cancer, and facial papules. In contrast, family 3 has no distinctive features usually associated with Cowden syndrome, although assessment of all at risk subjects has not been performed and the boys are still quite young. Cowden syndrome may be a more likely diagnosis in adolescents or adults because the cardinal features of GI polyposis and thyroid and breast carcinomas are of later onset than the findings of macrocephaly and developmental delay identified in children diagnosed with BRRS. As we accumulate more data on these children with PTEN mutations and the diagnosis of BRRS, they may develop features classically associated with Cowden syndrome.
Correlations between genotype and phenotype are beginning to be elucidated for Cowden syndrome and BRRS, with resulting implications for genetic counselling for cancer and related health risks. An association between the presence of a PTEN mutation and the development of cancer or breast fibroadenomas has been observed in both BRRS and Cowden syndrome. 13 Thus, aVected females in particular may have an increased risk of breast cancer, and we have recommended breast cancer surveillance beginning at puberty for the daughters in family 1. Mutations in the core phosphatase domain are common, and this domain appears to be a crucial region for the function of the tumour suppressor. 12 13 The PTEN mutation identified in family 1, R130X, is present in this core motif, and has been described in other families with either Cowden syndrome, BRRS, or features that overlap both of these conditions. 12 13 23 The PTEN mutation in family 2 has also been identified as a somatic mutation in a tumour (C Eng, unpublished data) and probably results in abnormal RNA processing with a truncated protein product. Since the father with overlapping BRRS/Cowden syndrome features had GI polyposis as well as thyroid cancer in his mid-20s, we have recommended that the son has an annual manual thyroid examination as well as thyroid function studies, and that he seek medical attention for the development of any breast or neck masses or rectal bleeding. The mutation in family 3 is at the same intronic position as that in family 2, although the symptoms appear to be more subtle in the two half brothers, who are still less than 6 years old. We have recommended that the same evaluations as those for family 2 be oVered to these brothers and their other at risk family members.
In summary, our three families with PTEN mutation confirmed BRRS illustrate the phenotypic variability within family members with this condition and the time course for the development of some of the manifestations. Macrocephaly appears to be the most consistent feature in BRRS, but may not be obvious and requires measurement and documentation. The natural history of this disorder suggests that the distinctive finding of penile macules in males may not appear until mid childhood, and that cognitive impairment, in addition to macrocephaly, may be a prominent feature of BRRS in many families. We suggest that postnatal overgrowth during childhood may be common in this condition, and other features such as high arched palate, joint hypermobility, and hypotonia may aid in diagnosis. With the availability of PTEN molecular analysis, genotype-phenotype correlations may be feasible. Our cases confirm the observation that the clinical features of BRRS and Cowden syndrome show significant overlap, and suggest that until these conditions are better understood, genetic counselling should include information about the risk of developing thyroid and breast cancers and gastrointestinal polyps for anyone with a documented PTEN mutation.
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EDITOR-Mitochondrial DNA (MtDNA) is highly polymorphic. Each person is estimated to diVer from another on average at about 25 base pairs among the 16 569 that comprise the mitochondrial genome. 1 Thus, only a small fraction of mtDNA variants are likely to be of pathogenic significance. Criteria currently used for determining the likelihood that a missense mutation is pathogenic include heteroplasmy (the percentage of mtDNA molecules within a cell or tissue harbouring a mutation), evolutionary conservation of the altered amino acid, a maternal inheritance pattern, absence of the mutation in controls, clinical features commonly linked to known pathogenic mtDNA mutations, and defects in mitochondrial morphologies and enzyme activities. 1 However, these criteria are inadequate for several reasons. Many mitochondrial missense mutations are homoplasmic. Pathogenic mtDNA mutations are typically characterised by incomplete penetrance, even when homoplasmic, presumably reflecting interactions with environmental and genetic factors. 2 As a result, inherited mtDNA mutations may manifest as "sporadic" disorders rather than with the classical maternal inheritance pattern. Biochemical assays may also be inconclusive, as the expression of a defect in mitochondrial function depends on the nuclear background and tissue type in which the mutation is studied. 3 4 As a result, mtDNA mutations identified in rare families or subjects with a putative mitochondrial genetic disorder are often of uncertain pathogenic significance.
Over 100 point mutations have been identified in mitochondrial genes in association with human disease, at least 45 of which are missense mutations in protein encoding genes. 5 However, frameshift mtDNA mutations are exceedingly rare. An acquired frameshift 4 bp deletion mutation was identified in the cytochrome b gene at nucleotide position (np) 14 787-14 790 in a patient with parkinsonism-MELAS overlap syndrome 6 and somatic mutations including frameshift mutations have been found in human cancers. 7 8 In contrast, inherited frameshift mutations in mtDNA have not previously been reported. We now report the identification of an inherited frameshift mutation in a patient with dystonia and maternally inherited cataracts. The normal base pair (T) is replaced by AC at np 3308 (T3308AC) in the mitochondrial gene encoding the ND1 subunit of complex I. Dystonia 9 10 and cataracts [11] [12] [13] have each been linked previously to complex I dysfunction and to mtDNA mutations but, for the reasons outlined above, the pathogenicity of the T3308AC mutation remains uncertain.
DNA was isolated by standard proteinase K and SDS digestion followed by phenol and chloroform extractions. DNA was isolated from muscle (III.4), fibroblasts (II.8), or blood (I.1, III.1, IV.1, IV.5, and IV.6). Each of these subjects (except IV.1) underwent neurological and ophthalmological examinations. Clinical and molecular data were unavailable from other family members. Polymerase chain reaction (PCR) amplification of mtDNA and sequencing on an ABI 377 automated sequencer (PerkinElmer) were performed as previously described.
14 PCR reactions for restriction digests were performed with primers at np 3207-3223 (upper) and 3414-3401 (lower). Restriction digests were performed with MsiI (New England Biolabs) and analysed by ultraviolet illumination of a 2% agarose gel permeated with ethidium bromide. The mutation eliminates the single restriction site for this enzyme. The normal 208 base pair (bp) PCR product is cut into two 104 bp fragments, but in the presence of the T3308AC mutation, a single 208 bp fragment remains. A normal control DNA sample was included in each assay to confirm complete digestion by the enzyme. Other PCR and sequencing primers have been published previously. 14 Immunoblotting of the ND1 subunit of complex I was performed using lysates of fibroblasts obtained from three aVected family members and one control. Samples (10 µg) were loaded and run on a 12% acrylamide minigel, rinsed, transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MD), and incubated in blocker containing primary antibody (1:500), as described previously.
horseradish peroxidase conjugated secondary antibody. Secondary antibodies were detected by chemiluminescence (Amersham ECL, UK).
The proband (III.4, fig 1) developed a unilateral (right) cataract in her late teens. At the age of 30 she experienced several episodes lasting 30 minutes each of bilateral paraesthesias in her arms and legs with right hemifacial paraesthesias and paresis. Neurological examination showed sensory loss and weakness in the right face, as well as right arm weakness. The following year, examination showed a right facial dystonia and diVuse hyperreflexia with a positive HoVman's sign on the left, but full strength and normal sensation. Plantar responses were flexor. Her sister (III.1) developed cataracts in her early teens with a severe left and mild right cataract. This sister's daughter (IV.1) died a few months after birth with a hypoplastic left heart, polycystic kidneys, and an ectopic pancreas. The maternal grandmother (I.1) developed a right cataract by the age of 40 years. There was no history of ocular trauma in any of the family members with cataracts.
An extensive evaluation of III.4 included normal brain computed tomography and magnetic resonance imaging. Electromyography and nerve conduction studies were normal. Muscle biopsy (right vastus lateralis) showed normal light and electron microscopic results. Cytochrome oxidase c staining was normal. No ragged red fibres were seen. Complex I activity, measured as rotenone sensitive NADH cytochrome c reductase activity normalised to citrate synthase, was normal. Cytochrome oxidase activity was normal. Citrate synthase activity was raised (11.08 µmol/min/g compared to 3.35 ± 1.1 for controls). Serum and cerebrospinal fluid lactates were normal. Serum ammonia was raised at 45 µmol/l (compared to normal of 9-33 µmol/l). Cerebrospinal fluid glucose and protein were normal with no cells or oligoclonal bands. Serum creatine kinase levels were normal.
Sequencing both the H and L strands of PCR amplified muscle derived DNA in III.4 showed a T to AC insertion/ deletion at np 3308 (T3308AC) (fig 2) . This converts an ATA (methionine) codon to AACA, creating a frameshift in the initiating methionine codon of the mtDNA gene encoding the ND1 subunit of complex I. The presence of a homoplasmic mutation was confirmed by the elimination of an MsiI (New England Biolabs) restriction site in III.4 as well as in each of her maternal relatives from whom DNA was available for analysis (I.1, II.8, III.1, IV.1, IV.5, and IV.6). The mutation was absent in 108 control subjects including 29 with Parkinson's disease and 23 with adult onset focal dystonia. An initiating methionine at this site is highly conserved evolutionarily. 16 Sequencing of the entire mitochondrial genome in subject III.4 showed 17 known errors or consensus changes in the Cambridge sequence. 17 Additional changes were observed as follows. Synonymous base pair changes: T6620C, C7028T, G11719A, G12007A, C12705T, and A14470G. Known polymorphisms in the non-coding D loop: C16223T, C16290T, G16319A, T16325C, T16362C, C64T, A73G, T146C, A153G, A235G, T310C, and C514CAC. Known polymorphisms in rRNA 
Figure 2 Electrophoretograms of subject III.4 (top) and a control showing a frameshift mutation at position 3308
where a T is replaced by an AC in subject III. 4 .
www.jmedgenet.com group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from genes: A663G, A1736G, and A2706G. Known polymorphisms in protein coding genes associated with an altered amino acid: A4824G (ND1), G8027A (COX II), and C8794T (ATP6). Mutations at non-conserved sites within the non-coding D loop (but not known polymorphisms): C461T, C505T, and a TT insertion at np 311. The TT insertion at 311 is not a known polymorphism, but a CC insertion at this site is a known polymorphism. An insertion of a C at 956 occurs in a non-conserved region of the 12S rRNA gene. A mutation identified at 14 280 (A to G) in the ND6 gene alters a non-conserved amino acid.
Immunoblotting detected the ND1 protein (apparent MW ∼33 kDa) in all fibroblast samples (fig 3) . Thus, the ND1 protein is expressed in subjects with the frameshift mutation. An additional, minor, cross reacting band of unknown identity and significance was also seen. Suspicion of a mitochondrial complex I gene mutation in this family was raised by the presence of dystonia and cataracts, each of which has been associated with complex I dysfunction and mtDNA mutations. [9] [10] [11] [12] [13] The origin of the complex I deficiency in dystonia is unknown. In one study, lung carcinoma derived cell lines expressing mtDNA from nine patients with focal dystonia did not manifest complex I deficiency. 18 However, the biochemical expression of mtDNA mutations is influenced by tissue type as well as nuclear background. 3 4 Thus, the role of mtDNA mutations in the complex I defect of patients with focal dystonia remains uncertain. Dystonia clearly can be a prominent manifestation of mtDNA mutations, as shown by missense mutations in a mitochondrial complex I gene in several families with dystonia plus Leber's hereditary optic neuropathy (LHON). [19] [20] [21] [22] Dystonia is commonly a prominent component of Leigh's syndrome, which can be associated with mtDNA point mutations or deletions. 23 24 Dystonia, along with other neurological deficits, was reported in a subset of aVected members of a family harbouring the LHON associated 11 778 complex I mutation, 14 and can be the presenting feature of the 3243 "MELAS" mutation. 25 Cataracts have also been reported as a clinical correlate of mitochondrial complex I dysfunction [11] [12] [13] and in patients with mtDNA mutations, including large deletions. 13 The occurrence of both dystonia and maternally inherited early onset cataracts in our patient suggested the possibility of a mtDNA mutation.
Though a mtDNA mutation was suspected in this family, the identification of a frameshift mutation was surprising given the mild phenotype and the lack of any previous reports of inherited frameshift mutations in human mitochondrial genes. Translation of the ND1 subunit normally begins at the initiating methionine codon at np 3307-9. An initiating methionine is highly conserved evolutionarily. 16 If translation begins at the 3307-9 codon for the mutant sequence, then the frameshift at 3308 would result in an asparagine (rather than methionine) as the initial amino acid and a premature stop codon after the 28th amino acid, whereas the full length ND1 subunit normally consists of 318 amino acids. Such an abnormality seems unlikely given the relatively mild clinical and biochemical features associated with the mutation. Alternatively, translation may begin in frame at the next methionine codon, which occurs at np 3313-5, resulting in a truncation of the first two amino acids (methionine and proline) at the amino terminal end of the ND1 subunit, with preservation of a methionine at the amino terminal end. Except for the initiating methionine, amino acids at the amino terminal end are not highly conserved evolutionarily. 26 Mutations involving np 3308 have been reported in several patients with neurological abnormalities including two with dystonia. Campos et al 16 reported a woman with transient ataxia and later seizures and marked generalised dystonia who harboured a missense point mutation at np 3308. Two other unrelated patients, each with multiple neurological deficits, also were found to harbour a missense point mutation at 3308. 27 One additional family with maternally inherited hearing loss attributed to the T7511C mtDNA mutation also harboured a T3308C point mutation 28 but it was not thought likely to be pathogenic as it was homoplasmic and had been reported previously in controls. 27 MtDNA mutations at np 3308 were not present in any of our 108 controls. Campos et al 16 also found no mutations at this site in 130 controls. In contrast, Vilarinho et al 27 reported that four of 150 controls harboured a point mutation at 3308. This may reflect the ethnic diVerences between these control groups. None of the combined 388 controls in these studies carried a frameshift mutation as found in the family reported here. However, the molecular consequences of a point mutation at this site may be identical to that of the T3308AC frameshift mutation, resulting in a truncation of the first two amino acids. The cellular impact of the T3308AC mutation is uncertain. A missense mutation in the initiating codon of the cytochrome c oxidase subunit II gene has been shown to result in lower levels of protein synthesis for this subunit. 29 In contrast, we found no evidence of altered ND1 expression in association with the T3308AC mutation, and muscle complex I activity was normal. The possibility remains that complex I activity could be altered in the basal ganglia, the primary site of pathology in many dystonia patients. 30 Furthermore, our complex I assay measures maximal enzyme activity ("Vmax"), and thus an eVect of the mutation on enzyme kinetics cannot be excluded. This is the first identification of an inherited frameshift mutation in a human mitochondrial protein coding gene. However, the pathogenic significance of this mutation remains uncertain. This case highlights the diYculties often encountered when interpreting associations between rare mtDNA variants and putative mitochondrial disorders. A common ancestor for COCH related cochleovestibular (DFNA9) patients in Belgium and The Netherlands bearing the P51S mutation EDITOR-Hearing impairment is extremely heterogeneous, both phenotypically and genetically. It is the most frequent form of sensory impairment in the western world, aVecting approximately 1/1000 newborns and approximately half of the people above the age of 80. 1 2 In all these cases hereditary factors are a prominent cause. So far, more than 60 loci for monogenic non-syndromal hearing impairment have been described and 14 responsible genes have been identified (Van Camp and Smith, Hereditary Hearing Loss Homepage http://dnalab-www.uia.ac.be/dnalab/hhh).
Balance problems are also are relatively frequent, but considerably less is known about the causes. Purely genetic forms of vestibular impairment are extremely rare and no genes have been identified yet. However, it is commonly known that many hearing impaired people also suVer from balance problems. Moreover, it is now recognised that many syndromes with genetic hearing impairment also show a dysfunction of the vestibular system. 3 The prevalence of vestibular dysfunction may be severely underestimated, as it often remains unnoticed until specialised vestibular tests are performed. Owing to the intimate relationship between the auditory and the vestibular systems, there are probably many genes with a function in both systems.
DFNA9 is the only form of hereditary non-syndromal hearing impairment where strongly marked vestibular involvement has been described. This locus has been mapped to chromosome 14q12-q13. 4 Progressive sensorineural hearing impairment is present, usually starting between the ages of 35 and 50 in the high frequencies. [5] [6] [7] This is paralleled by a gradually deteriorating sense of balance, leading to instability (most notably in the dark). Some, but not all patients periodically suVer from vertigo attacks associated with nausea, tinnitus, or aural fullness, which is reminiscent of the symptoms of Menière's disease. 5 Eventually, after a disease course of approximately 20 years, patients become severely to profoundly deaf across all frequencies and lose their vestibular function.
The identification of the gene responsible for DFNA9 was greatly helped by the availability of a cochlear specific cDNA library. 8 One of the transcripts in this cDNA library was a novel cochlear gene designated COCH-5B2, which was later renamed COCH. COCH was mapped to chromosome 14q12-13, making it a strong candidate gene for DFNA9. 9 Subsequent COCH mutation analysis in three DFNA9 families showed a missense mutation in each of them. 10 The predicted COCH protein has a length of 550 amino acids and consists of a signal peptide, a cysteine rich domain with homology to the factor C domain of the horseshoe crab Limulus (FCH domain), and two domains with homology to the von Willebrand factor A domain (vWFA1 domain and vWFA2 domain). All three mutations are located in the FCH domain.
Following the identification of the COCH gene, COCH mutation analysis was performed in several other DFNA9 families. In six Dutch and one Belgian family, a C→T point mutation at base pair 151 was found. 5 11 This mutation leads to the substitution of a conserved proline for a serine at position 51 of the COCH protein (P51S). Just like the three previously described mutations, this is a missense mutation residing in the FCH domain, and the substituted amino acid is conserved between the human, mouse, and chicken COCH homologues. In this study, eight additional families (or at least one of their members) were shown to carry the P51S mutation in the COCH gene. Fine mapping of the markers from the COCH region and haplotype analysis of markers flanking the COCH gene strongly suggested a single common founder for at least nine of these families.
Details of the families are shown in table 1. The clinical characteristics of family 1, 5 family 2, 7 12 13 family 3, 14 and families 4-7 6 11 have been described previously. Symptoms similar to those described were observed in families 8, 9, 11, and 12, as well as in the isolated patients 10, 13, 14, and 15. In family 8, a genome search was performed by the Mammalian Genotyping Center (Marshfield, USA), which mapped the disease locus to chromosome 14q12-13 (data not shown).
As the P51S mutation creates an extra site for the restriction enzyme DdeI, the mutation was analysed by PCR amplification followed by restriction enzyme digestion and gel electrophoresis, as described previously. 5 In normal controls, the 295 bp PCR product is digested into two bands of 247 and 48 bp, respectively. In heterozygous patients carrying the P51S mutation, two additional bands of 143 and 104 bp are visible on agarose gel electrophoresis.
The Whitehead database (http://www-genome.wi. mit.edu/) was screened with markers D14S262 and D14S1071 flanking the COCH region at 14q12-13, which yielded YAC contig WC14. YACs 746-F10, 732-A9, 855-C7, 814-E9, 857-D12, 905-B1, 925-C2, 952-D9, and 949-A9 were obtained from the UK Human Genome Mapping Project (HGMP, Harwell, UK). The relative marker order of seven polymorphic Généthon markers, as well as the position of the COCH gene, were determined by STS content mapping through PCR analysis. Microsatellite markers were analysed using a standard radioactive PCR assay. Primer sequences and allele frequencies for all markers used in this study were retrieved from the Généthon database. 15 The P51S mutation in the COCH gene has been found previously in seven families characterised by a combination of progressive sensorineural hearing impairment and vestibular dysfunction. 5 11 We analysed the presence of this mutation in a total of 29 additional families or isolated patients with similar symptoms. All families originate from Belgium or the southern part of The Netherlands. In eight of them, the P51S mutation was present, bringing the total number of P51S bearing families to 15. In the remaining 21 families without the P51S mutation, no further mutation analysis has been performed, so it is possible that they have a diVerent, as yet unidentified COCH mutation. General data about the families included in this study are summarised in table 1. Although all P51S bearing families originate from the same region, we found no genealogical evidence for a common ancestor.
Figure 1 YAC contig spanning the COCH region. YACs were screened for the diVerent markers by PCR. A positive signal is denoted by a black dot, and a stretch of positive signals is connected by a dashed line. The length of the YACs used for the mapping of the markers gave no clear answer to the physical distance between the markers (not shown
To investigate a possible founder eVect, we reconstructed the disease haplotypes for polymorphic markers flanking the COCH locus. This was complicated by the fact that on the Généthon map the order of these flanking markers was not completely resolved (not shown). In addition, the exact position of the COCH gene with respect to these markers was unknown. Therefore, we constructed a YAC contig spanning the COCH region and determined the marker order through PCR analysis on this contig. As a result of this analysis, the marker order and the position of COCH could be unambiguously determined (fig 1) . This marker order is diVerent from the one on the Généthon map, which locates D14S1034 proximal to D14S1021, D14S1040, and D14S1071, and D14S975 distal to D14S257. 15 The results of the haplotype analysis of the markers flanking the COCH gene are shown in table 2. Families 1, 4, 7, 8, 9, and 12 show exactly the same haplotype for all seven markers examined: 1-1-2-2-1-6-1 (for allele lengths and frequencies, see table 3) .
This common disease haplotype may also be present in family 11 (two brothers) and in patients 10, 13, and 15, but only partly in patient 14. In these cases, the disease haplotypes could not be unequivocally determined. Families 2, 5, and 6 have the same haplotype as families 1, 4, 7, 8, 9 , and 12 for the four markers that most closely flank the COCH gene on both sides. Marker D14S1071 has a diVerent haplotype and therefore the three most distal markers are not shared with the other families. In family 3, only marker D14S975 has the same haplotype as all the other families.
The P51S mutation in the COCH gene, which is responsible for progressive cochleovestibular impairment (DFNA9), had previously been found in seven families. In this study we have found the same mutation in eight novel families and isolated patients. This could indicate that either all 15 P51S bearing families share a common ancestor or that the P51S mutation represents a mutation hotspot that gave rise to several independent mutational events. Analysis of the disease associated haplotype of the polymorphic markers around COCH showed significant haplotype sharing in nine families and six of them (1, 4, 7, 8, 9, 12) shared haplotypes for all seven markers examined. The probability that six independent families would share a seven allele haplotype merely by chance is negligible (table 3) . Therefore, families 1, 4, 7, 8, 9, and 12 must be related to and originate from a common ancestor.
Most probably, families 2, 5, and 6 also originate from this common aVected ancestor. These latter families have four alleles in common with families 1, 4, 7, 8, 9, and 12, which are the ones that most closely flank the COCH gene (table 2) . One ancestral recombination between D14S257 and D14S1071 can explain the diVerent haplotypes of the distal markers D14S1071, D14S1040, and D14S1034. Taken together, a total of nine families have the identical Only the alleles mentioned in table 3 are given.
haplotype (1-1-2-2) for markers D14S262, D14S975, D14S1021, and D14S257 and it can be concluded that they all share a common ancestor.
Only family 3 has a haplotype that is distinct from the other families for the markers flanking COCH, with the exception of marker D14S975. However, as allele 1 is a very common allele for D14S975 (66%), sharing of it could be a coincidence. It cannot be excluded that the mutation in family 3 arose independently from the other families, but, on the other hand, this family may be more distantly related to the others and the shared interval around the COCH gene may be very narrow.
Families 10, 13, 14, and 15 represent isolated patients with the P51S mutation, whereas family 11 consists of two aVected brothers. Here, the disease haplotype could not be unambiguously determined. However, with the exception of patient 15, who is homozygous for allele 4 of marker D14S1021, the haplotypes observed in these isolated patients indicate that it cannot be excluded that they, too, are a carrier of the 1-1-2-2-1-6-1 haplotype. This question can only be resolved if more family members become available.
The 10 families in which the exact disease associated haplotype could be determined may allow an estimate of the number of generations passed since the common ancestor. Formulae to calculate this age rely on the probability of having recombinations in an interval with a known size. 16 17 The accuracy of these calculations, however, are heavily dependent upon and thus upon the accuracy of the genetic maps. However, the data obtained here indicate that the Généthon genetic map around the COCH locus is not reliable. Therefore, the intermarker distances around the COCH gene are unknown and even a rough estimate of the age of the mutation is not feasible. This question may be resolved in the future by an improvement of the map or by the sequencing of the COCH region as part of the Human Genome Project.
The geographical spreading of the P51S mutation may be another clue to the age of the mutation. The 15 families in which the P51S mutation was found contain more than 200 patients in Belgium and The Netherlands and there must be many more unidentified mutation carriers (table  1) . This makes the P51S mutation a frequent cause of late onset hearing impairment combined with vestibular dysfunction, at least in the Dutch and the Belgian populations. A systematic mutation analysis in other populations would indicate whether this mutation is also present elsewhere. A more general occurrence of the P51S mutation would indicate an ancient origin of the mutation or a mutational hotspot. This would imply that COCH is a major gene for cochleovestibular impairment in many different populations harbouring a recurrent mutation that can easily be screened for in a diagnostic setup.
The authors wish to thank all the families who contributed to this study. Gerard J te Meerman is acknowledged for his critical remarks on the manuscript. There are loci for ADPHSP on chromosomes 2p (SPG4, MIM 182601), 3 4 8q (SPG8, MIM 603563), 5 6 14q (SPG3, MIM 182600), 7 15q (SPG6, MIM 600363), 8 and 19q (SPG12). 9 In addition, we recently mapped an ADPHSP locus on chromosome 12q13 (SPG10, MIM 604187) in a large UK family, family 4. 10 This locus was narrowed to a 9.2 cM region between markers D12S368 and D12S83.
Clinical features and diagnostic criteria for family 4 have previously been described. 10 11 Briefly, subjects were classified as being aVected if they had lower limb hyperreflexia in addition to at least one of the following: progressive spastic gait abnormality, bilateral extensor plantar reflex, or bilateral sustained (>5 beats) ankle or knee clonus. Subjects were classified as being possibly aVected if lower limb hyperreflexia was present without other abnormal signs and as being normal if they had an entirely normal neurological examination. Thirteen members of family 4 are aVected by ADPHSP and the family has a relatively young mean age at onset of 10.8 (SD 9.6) years (range .
We have now genotyped additional markers D12S803, D12S390, D12S270, D12S1618, and D12S355 for subjects from family 4, using previously described methods. 10 Primer sequences for these markers are available from the Généthon microsatellite linkage map 12 or from the Marshfield Medical Research Foundation website. Haplotypes were constructed for these and for previously genotyped markers (fig 1) . Obligate recombination events in two aVected subjects (III.5 and III.9) redefine the centromeric boundary of the SPG10 region at D12S270, and an obligate recombinant event in aVected subject IV.1 redefines the telomeric boundary at D12S355. These recombination events narrow the SPG10 candidate region to 6.95 cM (Marshfield Medical Research Foundation website).
A database search (Online Mendelian Inheritance in Man) was carried out to identify candidate genes within the SPG10 critical region. The neuronal sodium channel gene SCN8A is located at chromosome 12q13, close to marker D12S368. 13 It is expressed in neurones throughout 1   1  3  4  5  6  7  8  9  2   7  1  5  6  1  8  9  7  7  13  7  1   2  1  3  6  1  5  13  12  15  11  7  1   D12S345  D12S85  D12S368  D12S803  D12S390  D12S270  D12S1618  D121586  D12S1691  D12S355  D12S83  D12S326   1  7  12  10  2  3  4  5  6  8  9   3  1  2   11   2   3  1  5  5  5  6  14  7  5  10  13  1   2  1  3  6  1  5  13  12  15  11  7  1   D12S345  D12S85  D12S368  D12S803  D12S390  D12S270  D12S1618  D121586  D12S1691  D12S355  D12S83  D12S326   D12S345  D12S85  D12S368  D12S803  D12S390  D12S270  D12S1618  D121586  D12S1691  D12S355  D12S83  D12S326   12  1  5  5  2  1  1  7  6  12  3  1   2  1  3  6  1  5  13  12  15  10  13  1   5  4  1  7  3  1  16  1  6  16  5  6   2  1  3  6  1  5  13  12  15  11  7  1   1  1  2  5  6  6  1  5  6  15  8  5   2  1  3  6  1  5  13  12  15  11  7  1   3  1  2  7  5  6  6  7  17  15  7  8   2  1  3  6  1  5  13  12  15  11  7 the central and peripheral nervous systems. 14 15 Mice homozygous for null mutations in SCN8A (med and med tg ) develop progressive hind limb paralysis and muscle atrophy, with death in the juvenile period. 14 16 The progressive paralysis in mouse SCN8A null mutants is caused by functional denervation of skeletal muscle, with normal motor neurone number and diameter. 17 Although ADPHSP is pathologically characterised by "dying back" of the terminal ends of corticospinal tract axons, 18 we considered there to be suYcient overlap between the ADPHSP phenotype and the SCN8A mouse null mutant phenotypes to investigate this gene as a candidate for the disease.
The 26 exons (with flanking intronic sequence) of SCN8A were amplified by polymerase chain reaction, as previously described, 13 using DNA from aVected subject III.2. Each exon, with its flanking intronic sequence, was sequenced manually, as previously described, 13 or with dye terminators (Perkin Elmer, Foster City) on an ABI377 automated sequencer (Perkin Elmer). Two previously identified single nucleotide polymorphisms were detected, a C to T in intron 19, position -27 from exon 20, and a C to T in exon 22, at position +90. 13 Neither of these variants change the amino acid sequence. We also detected a T for C substitution in exon 14 at position +175 (fig 2A) . This new variant results in an arginine to cysteine substitution in the SCN8A protein at amino acid 1026, within a conserved region of the second cytoplasmic loop (fig 2B) . The T for C substitution can be detected readily, since it abolishes an Fnu4HI restriction site. We examined the segregation of this new variant in the family by carrying out PCR amplification of exon 14, digestion of PCR product with Fnu4HI, followed by agarose gel electrophoresis. The T for C variant segregated completely with the disease, except in aVected family members III.5 and III.9, who were recombinants for this new SNP (fig 2C) . These results exclude SCN8A from the SPG10 candidate region, with a likely placing centromeric to D12S1618. This location is consistent with the physical mapping of SCN8A to a YAC containing D12S368. 13 The frequency of the exon 14 SNP was determined by genotyping 80 parents from the CEPH pedigrees (CEPH website) and a panel of unrelated, white United Kingdom subjects, black African subjects, and Japanese subjects. The T for C substitution was present in 3/80 CEPH parents (3/160 chromosomes, 1.9%), 2/39 of the UK subjects (2/78 chromosomes, 2.6%), in 0/44 black African, and 0/27 Japanese subjects. To our knowledge, this is the first relatively common coding variant described within an ion channel gene. Further studies will be required to determine whether this polymorphism has any functional eVect on the SCN8A protein, or whether it confers any predisposition to polygenic diseases which may arise from ion channel disorders.
To date, four diVerent classes of genes have been implicated in HSP. X linked spastic paraplegia is caused by mutations in the cell adhesion molecule L1-CAM 19 and mutations in a myelin gene, the proteolipid protein gene. 20 One form of autosomal recessive HSP is caused by mutations in a nuclear encoded mitochondrial gene (paraplegin) which has metalloprotease and chaperone function. 21 Finally, a gene for the most common form of ADPHSP, spastin, encodes a protein which may be involved in the structure of the nuclear proteosome. 22 The diversity of HSP genes suggests that the neurodegeneration seen in HSPs may be a final common pathway for a number of processes, some of which may involve novel proteins. This makes selection of candidate genes problematical. Identification of additional SPG10 linked families will be crucial to narrow the candidate region and facilitate positional cloning of the SPG10 gene. Cytogenetic and molecular study of a jumping translocation in a baby with Dandy-Walker malformation EDITOR-Jumping translocations are rare chromosomal events in which a donor chromosome segment is translocated to various recipient chromosome sites. Jumping translocations were initially described in constitutional chromosome syndromes, 1 2 but the majority of published cases have been observed in haematological malignancies, where their presence has been related to poor prognosis. 3 4 Most jumping translocations involve acrocentric chromosomes and a characteristic feature is that breakpoints usually concern areas of repetitive DNA (telomeric, centromeric, or heterochromatic regions). Recipient chromosome involvement seems to be randomly distributed but with a preferential involvement of telomeric segments. This has led to the hypothesis that repetitive telomeric sequences could be implicated in the occurrence of jumping translocations, as suggested by FISH studies which have reported the presence of interstitial telomeric sequences at the junction sites of jumping translocations. 5 6 However, the molecular basis underlying these complex chromosomal rearrangements is not well understood.
Constitutional jumping translocations are extremely rare and are usually associated with various phenotypic abnormalities. We report the finding of a jumping translocation in a baby with Dandy-Walker malformation. DandyWalker malformation consists of the triad (1) hypoplasia or absence of the vermis, (2) upward displacement of the falx, lateral sinuses, and torcular, and (3) a large, thin walled retrocerebellar cyst formed by the roof of the fourth ventricle. Most Dandy-Walker malformations are sporadic. The Possum database reports six autosomal dominant syndromes and 37 autosomal recessive syndromes which can be associated with Dandy-Walker malformation. However, in these disorders, Dandy-Walker malformation is always one feature of a larger spectrum of anomalies. Various cytogenetic abnormalities have been reported, but to date no consistent chromosomal aberration has been recognised. 7 8 The present study combines molecular and cytogenetic investigations, including FISH and PRINS labelling procedures, to characterise a constitutional jumping translocation.
The patient is a baby boy, the second child of healthy, consanguineous parents (the parents are double third cousins). The family history is otherwise unremarkable. Consent was obtained from the parents for genetic studies. At the time of birth, the mother and father were 26 and 34 years old respectively. There was no history of maternal exposure to environmental hazards during pregnancy. The pregnancy was uneventful until sonographic examination at 39 weeks' gestation suggested partial agenesis of the vermis. Fetal sampling for chromosome analysis was not undertaken. The baby was delivered at 40.5 weeks' gestation; birth weight, length, and head circumference were 3260 g, 50 cm, and 34 cm, respectively. Apgar scores were 8 at one minute and 9 at five minutes. The baby was referred to our genetics service at the age of 1 month. At this time, weight, height, and head circumference were 5250 g (+3 SD), 57 cm (+2 SD), and 40.5 cm (+2 to +3 SD), respectively. He showed no facial dysmorphism; physical examination showed a small median mass of the occipital soft tissues and bilateral deep plantar furrows, but was otherwise normal. Skull x ray showed an occipital bone defect. MRI showed (1) hypoplasia of the cerebellar vermis (only a part of the posterior and anterior segments are visible), (2) upward displacement of the cerebellar falx, and (3) a retrocerebellar cyst communicating with the fourth ventricle. These features led to a diagnosis of DandyWalker malformation. Neurological developmental milestones were normal at the age of 1 month. At the age of 5 years, neurological examination and psychomotor development were normal. The patient walked at 16 months, language skills were acquired normally, and school performance is normal for age. Initial cytogenetic investigations in the patient were performed on peripheral blood lymphocytes and then subsequently repeated on a second blood sample and skin biopsy. Chromosomes were studied according to standard procedures for RHG banding. der (2) der (2) der (12) der (2) der (2) der(6) der (6) 2 2 t(2;5)(p12;q35)
der (2) der (2) der (5) der (5) 2 2 t(1;2)(p36;p12) Partial R banded karyotype Idiogram indicating the specific breakpoints 1 1 der(2) der (2) der (1) Dual colour FISH labelling was performed with commercially available whole chromosome paints for chromosomes 1, 2, 5, 6, and 12, according to the suppliers' instructions (Oncor, Gaithersburg, MD). Specific painting probes were combined as follows: biotinylated chromosome 2 specific paint with chromosome 1, 5, 6, or 12 specific paint labelled with digoxigenin. Biotinylated painting was visualised using fluorescein-avidin whereas detection of digoxigenin was done with antidigoxigeninrhodamine.
Specific labelling of subtelomeric regions 1p, 2q, 5q, 6q, and 12q was performed using subtelomeric specific probes. Probes for 2p, 5q, 6q, and 12q were direct fluorophore labelled probes provided by Vysis (Vysis Inc, Downers Grove, IL). The YAC probe 762B5, specific for the subtelomeric region 1p, was a gift from Dr Rocci (Barri, Italy). This probe was labelled by nick translation with digoxigenin-11-dUTP (Boehringer Mannheim, Meylan, France) and used under the same conditions as the purchased subtelomeric probes. The subtelomeric probes correspond to loci estimated to be within 300 kb of the end of the chromosomes.
Telomere repetitive sequences were labelled by PRINS using the telomeric consensus primer (CCTAA)7. PRINS experiments were performed as previously described. 10 Fifty µl of a reaction mix composed of the telomeric consensus primer, a nucleotide mixture including fluorescein-dUTP, Taq DNA polymerase buVer, and 2 units of Taq DNA polymerase (Boehringer Mannheim) was used. PRINS reactions were performed on a programmable thermal cycler equipped with a flat plate block. The denatured slides were put on the plate block and the reaction mixes placed on the slides and overlaid with coverslips. The reaction cycle consisted of two programmed steps: 10 minutes at the specific annealing temperature of the primer (60°C) and 20 minutes at 72°C in order to allow the in situ nucleotide chain elongation. At the end of the reaction, slides were washed in 2 × SSC-0.5% Tween 20 and then directly counterstained with propidium iodide in Vectashield antifade solution (Vector Laboratories, Burlingame, CA).
Combined FISH and PRINS experiments were also performed according to the previously reported protocol. 11 We used a centromeric repeat probe specific for chromosome 2 (Oncor) and the consensus telomeric primer (CCTAA)7.
Fluorescent signals generated by FISH or PRINS were visualised by using a Leitz DMRD microscope equipped with appropriate filters. Combined FISH and PRINS labelling experiments were analysed by confocal microscopy. Optical sections were sampled with a confocal Nikon microscope. Images were transferred to a Power Macintosh computer and standard software tools (Adobe Photoshop 5.0) were used for image analysis.
The parental origin of chromosome 2 was investigated by PCR analysis of two microsatellite markers, D2S337 and D2S2232, located on both sides of the breakpoint 2p12 (respectively in 2p14 and 2p11). DNA was extracted from peripheral blood of the proband and his parents. Oligonucleotide primer sets were obtained from the Genethon. PCRs were performed in a total volume of 50 µl containing 200 ng genomic DNA, 5 µl of 1 × PCR buVer (10 mmol/l Tris-HCl, pH 8.3, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.01% (w/v) gelatin), 200 µmol/l each of dNTPs, 0.15 µl dUTP-R110, 0.2 µmol/l primers, and 1 U of Taq DNA polymerase). After an initial denaturation (96°C for 2 1 ⁄2 minutes), the PCR was carried out for 30 cycles consisting of 20 seconds at 94°C, 20 seconds at 55°C, 40 seconds at 72°C, followed by a final extension step of 72°C for 10 minutes. One µl of each reaction product was mixed
Figure 2 Examples of dual colour painting of donor chromosome 2 (in red) and the four recipient chromosomes (in green): (A) translocation t(1;2)(p36;p12), (B) translocation t(2;5)(p12;q35), (C) translocation t(2;6)(p12;q27), (D) translocation t(2;12)(p12;q24).
with 2 µl of formamide, 0.5 µl of molecular weight marker, and 0.5 µl of loading buVer. The mix was denatured for three minutes at 90°C and 1 µl was loaded onto a denaturing 4% polyacrylamide gel (36 cm × 20 cm × 0.2 mm thick). The electrophoresis conditions were one hour 40 seconds at 3000 V and 51°C. The analysis was carried out with the Genescan 2.1 software (Applied Biosystems) on an ABI 377.
Chromosome studies on the initial blood sample and control blood and fibroblast cultures showed four diVerent cell lines: 46,XY,t(1;2)(p36;p12)/46,XY,t(2;5)(p12;q35)/ 46,XY,t(2;6)(p12;q27)/46,XY,t(2;12)(p12;q24). A summary of the cytogenetic data is given in table 1 and partial ideograms and RHG banded karyotypes are presented in fig 1. This constitutional mosaicism was consistent with a jumping translocation involving almost the entire short arm of chromosome 2 (donor chromosome) alternately transferred to the telomeric regions of four recipient chromosomes (chromosomes 1, 5, 6, and 12). The predominant cell line in both initial and control samples was t(1;2)(p36;p12) (table 1). The parents' chromosomes were normal with RHG banding. Derivative chromosomes resulting from the jumping translocation were confirmed in metaphase spreads by the use of whole chromosome painting probes (fig 2) . No normal or unbalanced chromosome complements were found. However, dual colour whole chromosome painting did not show evidence of translocation of chromosomal material from recipient chromosomes 1, 5, 6, and 12 onto another chromosome. Specific subtelomeric FISH labelling ( fig 3) showed that these sequences were not translocated between chromosome 2 and the four recipient chromosomes, whereas consensus PRINS labelling of telomeric repetitive sequences clearly indicated the presence of interstitial telomeric sequences on the recipient chromosomes (at the junction sites of the translocation) (fig 4) , and at both ends of the derived chromosome 2 ( fig 5) .
The results of microsatellite marker analysis of chromosome 2 are given in fig 6. Both paternal and maternal alleles were present in the proband for each locus. This heterozygosity was not in favour of uniparental disomy for chromosome 2.
The proband is the product of a consanguineous union. He shows signs of Dandy-Walker malformation and normal neurological evaluation at the age of 1 month. Repeat chromosome studies in blood and in fibroblasts, as well as chromosome painting experiments, show de novo mosaicism for a jumping translocation in which chromosome 2p is alternately transferred to various recipient chromosomes (1, 5, 6, and 12) . There is no evident relationship between the phenotype and the chromosome abnormality in our patient. Subtelomeric rearrangement does not seem to contribute to the phenotype; however, mosaicism cannot be totally excluded and it is also possible that the translocation breakpoint on chromosome 2 has disrupted the sequences of one (or more) genes implicated in Dandy-Walker syndrome. As shown in a recent systematic study, cryptic deletions may be an important cause of disease in patients with apparently balanced chromosome rearrangements. 12 The possibility of uniparental disomy of chromosome 2, which might be related to the malformation of the proband, has been minimised by the microsatellite analysis.
At present, little is known about the origin of jumping translocations. In three other reports of constitutional jumping translocations, interstitial telomeric sequences have been observed. 5 13 14 Interstitial telomeric sequences thus seem to be a common feature of constitutional jumping translocations occurring at telomeric recipient sites. The presence of interstitial telomeric sequences was not systematically observed in cases of jumping translocations associated with haematological disorders. 15 Nevertheless, failure to observe interstitial telomeric sequences may be because of an inherent limitation of in situ labelling procedures for the detection of submicroscopic telomeric sequences.
The results of our classical cytogenetic investigations and whole chromosome painting suggested a simple transposition with fusion between the 2p12 segment and the telomeres of recipient chromosomes rather than a reciprocal exchange, since recipient chromosomes appeared cytogenetically intact. The observed subtelomeric labelling was in accord with this interpretation since no translocation of subtelomeric sequences was observed between chromosome 2 and the four recipient chromosomes. Nevertheless, this does not rule out the possiblity of translocations occcurring distal to subtelomeric sequences since the subtelomeric probes are usually located between 40 and 300 kb from the telomeres.
PRINS labelling showed interstitial telomeric sequences at the telomeric breakpoint of the recipient chromosomes and at the broken end of chromosome 2. These data may suggest that the telomeric repeat sequences of the recipient chromosomes were partially deleted and translocated onto the proximal end of the broken chromosome 2, which would be in favour of a translocation event. However, for the jumping translocation we report, this event would have to occur four times which seems unlikely.
An alternative explanation for the presence of telomeric sequences at the proximal end of der(2) is the de novo formation of telomeric sequence at the end of the der(2). This has been shown to occur through healing of broken chromosomal ends by seeding of telomeric sequences and requires the expression of telomerase in the cell. 16 The stabilisation of broken chromosomes could also result from the recognition by telomerase of internal telomere-like sequences proximal to the breakpoint. 17 In many eukaryotes, the ability to heal broken chromosome ends by telomeric addition is a well documented phenomenon and appears to be controlled by developmental factors. 18 This phenomenon occurs early in embryonic development, shortly after zygote formation when telomerase activity is still eYcient. 19 This information contributes to an understanding of when our proband's rearrangement occurred. Mosaicism was found in blood and skin cultures of the patient. For both tissues, there is one largely predominant cell line, involving chromosomes 1 and 2. No chromosomally normal cells were found. It seems likely that chromosome 2 is prone to breakage. Breakage could have occurred in four (or more) diVerent cell lineage precursors and the broken chromosome 2 fragment translocated to the end of diVerent chromosomes.
The presence of interstitial telomeric sequences is considered to represent a form of chromosome instability and, consequently, these sequences could play a role in generating the observed mosaicism. 20 Although the telomeric repeat nucleotide sequences are similar in telomeres and intrachromosomal areas, their diVerent locations (terminal or interstitial) could contribute to diVerential organisation of the chromatin in the two domains, as shown by the variable eVect of exonuclease on terminal and interstitial telomeric sequences. 21 In jumping translocations, the presence of interstitial telomeric sequences on a receptor chromosome makes this chromosome unstable and makes the transferred fragment susceptible to "jumping" from one telomere to another. An alternative suggestion is that preferential involvement of telomeric regions in jumping translocations could result from the stabilisation of chromosome breakage by a telomeric capture process. Our report provides further evidence that the jumping process and the presence of interstitial telomeric sequences could be related. The preferential involvement of interstitial telomere-like sequences in chromosome breakage, rearrangement, and instability could be the result of quantitative or qualitative diVerences in the constitution of proteins associated with telomeric repeat sequences according to their location. It would be interesting to determine whether specific telomeric proteins such as TRF1 and TRF2 are present in interstitial telomere sequence regions. 22 The elucidation of the underlying mechanism and the role of telomeres in the jumping translocation process will require studies combining cytogenetic and molecular technologies. In the future, the understanding of jumping translocation processes will greatly benefit by the molecular cloning of breakpoints as well as the search for specific genes or sequences involved in the occurrence of these rare chromosomal events. 1 DS is a major cause of mental retardation and congenital heart disease in humans, but is also associated with other major features, such as characteristic facies, skeletal abnormalities, and an increased risk of leukaemia and Alzheimer's disease. In most cases (95%), the trisomy of chromosome 21 involves the whole chromosome through maternal (most frequent) or paternal non-disjunction, whereas in some cases (4%) Down syndrome is the result of an unbalanced translocation. Among the latter, a very small proportion of cases are the result of partial trisomy of chromosome 21 arising either from non-Robertsonian translocations or from intrachromosomal duplications. 2 The DS phenotype is also found in cases (1%) of mosaicism of trisomy 21. 3 During the last decade, considerable progress has been made towards discovering the gene content of chromosome 21, but the functions of most of these genes and their specific contributions to the final DS phenotype still remain unknown. The identification and characterisation of cases of partial trisomy of chromosome 21 has allowed a phenotypic map of this chromosome and DS to be constructed. Clinical and molecular studies of these cases have suggested that most of the phenotypic features of DS are the result of the triple dose of the genes contained in the region around marker D21S55. This region is called the Down syndrome critical region (DSCR). [4] [5] [6] However, recent evidence suggests that genes outside this region may also contribute to the DS phenotype. 7 To evaluate DS patients clinically, a checklist of 25 clinical traits was first reported by Jackson et al 8 10 11 and the sequenced clones are constantly released to the public databases.
We report here the clinical findings of a patient with a partial trisomy of chromosome 21 resulting from a dup(21q22.1-qter). The patient has some clear signs of DS but also lacks some of the characteristic features of the disorder. The extent of the duplication was characterised by FISH. It extends from marker D21S304 to the telomere and the centromeric breakpoint is localised in the chromosomal region encompassed by YAC 280b1, centromeric to the SOD1 gene.
The patient is a boy from Sâo Paulo, Brazil. The family history is unknown and the patient is currently in a Shelter House of the Brazilian Government waiting for adoption. The patient was first seen at the age of 1 year 10 months. The first examination showed some clinical features suggestive of DS, such as oblique eye fissures, low set ears, high and narrow palate, mild hypotonia, and protruding tongue, as well as delayed psychomotor milestones. A karyotype was performed then and showed 46,XY,21q+. This cytogenetic result prompted a further clinical examination of the patient according to the protocols described by Epstein et al. 9 At this second examination, the patient was 2 years 11 months old (fig 1) .
Chromosome analyses were performed on standard phytohaemaglutinin (PHA) stimulated lymphocyte cultures from peripheral blood. Some chromosome spreads were G banded and 5-bromo-2'-deoxyuridine (BrdU) was added to two cultures to perform R banding. We generated painting probes from chromosome 21 in order to elucidate the origin of the extra material. We used the hybrid (mouse-human) cell line WAV-17 that has chromosome 21 as its only human component. 12 We extracted the DNA and performed inter Alu-PCR. 13 To define the partial trisomy further, YACs from the long arm of chromosome 21 were selected 10 and also amplified by inter Alu-PCR. A total of 14 YACs were hybridised (fig 2) . Probes were labelled and hybridised as described elsewhere.
14 Twenty metaphases and 50 interphase nuclei were studied for each probe.
The clinical evaluation of the patient at the age of 2 years 11 months showed short stature, brachycephaly, flat facies, oblique palpebral fissures, epicanthic folds, flat nasal bridge, high palate, malformed and low set ears, short and broad hands with clinodactyly of the fifth finger, and moderate mental retardation. The patient also had delayed psychomotor development; he sat at the age of 8 months and walked at 16 months (table 1, fig 1) . Dermatoglyphics were normal and an electrocardiogram showed that the patient had an incomplete block of the right branch (with no charge), but no major congenital heart defect. Abdominal scan and audiometry were normal. The cytogenetic study performed with both G and R banding showed that out of 45 metaphases analysed, 37 had extra material on chromosome 21q. A more detailed study of the case by FISH using a painting probe that covers the whole long arm of chromosome 21 showed that all the extra material attached to one chromosome 21 was derived from the same chromosome. FISH performed with YACs along the q arm of chromosome 21, showed that the patient had a duplication 21q22.1→qter. The contig of YACs used showed that the breakpoint was located just proximal to SOD1, within YAC 280b1, which contains markers DS21S304 to D21S306 (fig 2) . All distances between the double signals on the dup(21) were identical for all YACs studied. All the metaphases analysed by FISH showed the duplication, discounting the possibility of mosaicism observed using banding techniques (fig 3) .
We have identified a case of partial trisomy of chromosome 21 and a DS phenotype caused by duplication of 21q22.1→qter. Using FISH with YAC probes from the long arm of chromosome 21, we have identified the extent of this duplication as well as its orientation. The trisomic region spans marker D21S213 to the telomere, which covers about 13 Mb of the chromosome, as judged from the physical map. 15 Comparison of the clinical features resulting from partial trisomy of chromosome 21 has provided the basis for construction of the DS phenotypic map. The coverage of chromosome 21 by a panel of YAC clones and the use of these YACs in FISH analyses allows us to combine the phenotypic information from our DS patient with a fairly accurate molecular definition of the duplicated region. This approach is much faster and more precise than the dosage studies or polymorphic marker methods previously used. 6 7 The phenotypic map of DS constructed by Korenberg et al 7 assigned 25 features to regions spanning 2 to 20 Mb and they concluded that DS is a contiguous gene syndrome with duplications distinct from distal 21q22 contributing to the main features of DS. Given that the partial trisomy of chromosome 21 in the patient does not involve any other chromosome, it further supports the hypothesis that the genes contained in the region from 21q22 to the telomere are responsible for the majority of the features of DS, as previously reported by Korenberg et al. 7 Three other cases have been reported with a similar duplicated region. 6 7 14 As shown in table 1, the case reported here further confirms that the majority of the phenotypic features of DS are contained in the region triplicated in the four cases. However, the penetrance of the majority of the clinical features of DS is not complete, so to establish the correlation only the presence (not the absence) of a given trait should be taken into account. When the three published cases of DS with a similar partial trisomy and the present case are compared, we can see that almost all the physical traits typical of DS are present, perhaps with the exception of the furrowed tongue which has an overall frequency of 55% in the DS population. 16 One of the diYculties in the construction of a phenotypic map of DS, based on cases of partial trisomy, is that a large proportion of these cases have in addition other chromosomal abnormalities which may contribute to the clinical findings. Our patient presents no other chromosomal abnormality, so all his clinical traits can be assumed to be associated with the duplication of chromosome 21. However, we have established comparisons with other cases with a very small partial monosomy of another chromosome, which may have a very small contribution to the final phenotype of the patients.
With the continued development of molecular cytogenetic tools and the availability of methods and probes for the accurate determination of the chromosomal rearrangements in each case, phenotype/genotype correlations can be obtained with a high degree of accuracy and diagnosis can be performed at the molecular level with a high degree of certainty. We present four new cases of nonhomologous, non-Robertsonian dicentric autosomes with centromeres distinguishable by standard cytogenetic techniques; two were inherited from asymptomatic carriers and two occurred de novo in children with deletion 18p syndrome phenotype.
Metaphase chromosomes were obtained from peripheral blood or amniocytes harvested according to standard protocols. GTG banding was performed on all cases. C banding using Ba(OH) 2 was used. Fluorescence in situ hybridisation (FISH) of alpha satellite sequences was performed on metaphase chromosomes according to the protocols provided by ONCOR. FISH with a 16q subtelomeric sequence was performed according to the protocol provided by AL Technology.
Case 1 was ascertained through amniocentesis at 14 weeks' gestation for advanced maternal age. The mother was a 41 year old gravida 3, para 2, aborta 0. The couple's family history was unremarkable. The GTG banded karyotype at a resolution of approximately 350 bands showed the presence of an apparently balanced translocation between the telomeric regions of 16q and 22p, creating a dicentric 45,XY,dic(16;22)(q24;p11.2). The phenotypically normal father was proven to carry the same translocation which, in his case, had arisen de novo ( fig  1A) . The dicentric showed only one primary constriction on G banding in all cells analysed in the fetus and his father, corresponding to chromosome 16 centromere. It hybridised with probes for the alpha satellite sequences of chromosomes 14 and 22 ( fig 1F) and for the subtelomeric sequence of the long arm of chromosome 16 ( fig 1E) . After genetic counselling, the couple decided to continue the pregnancy. However, in the 20th week of gestation, intrauterine fetal death (IUFD) was diagnosed. The fetus showed severe autolytic changes and had measurements compatible with intrauterine death at 15 weeks. External and internal pathological examination showed no malformation. Therefore, post-amniocentesis intrauterine fetal death was not excluded.
Case 2 was ascertained through fetal tissues received for IUFD at 32 weeks of gestation. The mother was a 29 year old gravida 3, para 1, aborta 1. The second trimester screening ultrasound at 18 weeks' gestation showed an isolated choroid plexus cyst. At 32 weeks, IUFD was diagnosed. Necropsy showed a growth retarded male fetus with a weight of 650 g and with crown-heel length of 32 cm. The phenotype was consistent with trisomy 18, including mild hirsutism, small mouth, overlapping fingers, rocker bottom feet, short hallux, nail hypoplasia, interventricular septal defect, and Meckel's diverticulum. [12] . One cell line was an unbalanced male karyotype composed of a dicentric chromosome formed by an apparently balanced translocation between the short arms of chromosomes 14 and 18, as well as two normal chromosomes 18, resulting in trisomy 18. The other cell line was female, carrying the same dicentric with a chromosome count of 45 as a result of the formation of the dicentric. This finding could be explained by the presence of a female resorbed twin or by maternal contamination. The latter was more likely since the phenotypically normal mother did indeed carry the dicentric ( fig 1B) . The grandmother's karyotype was normal. The maternal grandfather could not be reached. The dicentric showed only one primary constriction at the site of chromosome 18 centromere in all cells analysed from the fetus and the mother. C banding confirmed the presence of two blocks of centromeric heterochromatin ( fig 1I) . Case 3 was born at 40 weeks of gestation after an uneventful pregnancy. The birth weight was 3960 g (75th centile), birth length was 54 cm (90th centile), and OFC was 36.5 cm (75th centile). Apgar scores were 8, 9, and 10 at one, five, and 10 minutes respectively. Karyotyping was requested at the age of 4 1 ⁄2 years because of psychomotor retardation. He was globally delayed with severe diYculties in language. At the age of 4 1 ⁄2 years, he could walk, hop, and ride a tricycle but had diYculty with his balance, could only speak 20 words with no sentences, and would not play with other children. Physical examination showed mild dysmorphic features, including a long face, bilateral epicanthic folds, bulbous nose, large and slightly anteverted ears, high arched and narrow palate, microretrognathia, pectus excavatum, and bilateral fifth finger clinodactyly. Thyroid evaluation was normal. The karyotype, 45,XY,dic(13;18)(p12;p11.2), showed an unbalanced translocation between the short arms of chromosomes 13 and 18 creating a dicentric chromosome with a deletion of the distal band of chromosome 18p, 18p11.3 ( fig 1C) . There was only one primary constriction corresponding to chromosome 18 centromere in all cells analysed. FISH with probes against the alpha satellites 13/21 ( fig 1G) and 18 (fig 1H) confirmed the presence of two centromeres.
Case 4 was first evaluated at 20 months of age because of developmental delay and dysmorphic features. She was born at 37 weeks of gestation after an uneventful pregnancy. Her birth weight was 2565 g (5th-10th centile), birth length was 47 cm (10th centile), and OFC was 30.8 cm (<5th centile). At birth she was diagnosed with transposition of the great arteries and operated on as a neonate. At 3 months of age she suVered from a urinary tract infection and renal ultrasound showed mild bilateral hydronephrosis. Her psychomotor development was de- group.bmj.com on July 7, 2017 -Published by http://jmg.bmj.com/ Downloaded from layed.She started to crawl at 14 months and was not walking at 20 months; she was not speaking any words at the time of the first evaluation. At that age, she weighed 9.0 kg (<5th centile), her length was 79 cm (10th-25th centile), and her OFC was 45.5 cm (2nd centile). Physical examination showed dysmorphic features, including bilateral ptosis of the eyelids (right>left), mild bilateral epicanthic folds, bulbous nose, large and anteverted simple ears, central dimple on the chin, slightly short neck, mild pectus excavatum, bilateral 5th finger clinodactyly, partial 2-3 syndactyly of the toes, and a blind sacral dimple. Ophthalmological evaluation showed myopia. Growth hormone and IgA levels were normal. The karyotype, 45,XX,dic(13;18)(p11.2;p11.2), showed an unbalanced translocation between the short arms of chromosomes 13 and 18 creating a dicentric chromosome with a deletion of the distal band of chromosome 18p, 18p11.3 ( fig 1D) . All cells analysed showed one primary constriction at the level of chromosome 18 centromere. The derivative chromosome hybridised with alpha satellite sequences of chromosomes 13/21 and 18.
The four cases reported here bring to 26 the total number of non-Robertsonian heterodicentric autosomes reported since the seventies (table 1). Many of these are associated with a deletion of the chromosomes involved (13/26) and, consequently, with phenotypic abnormality. This significant number of unbalanced cases could be the result of a bias of ascertainment. In those cases parental karyotypes were normal, as expected. Phenotypically normal people have also been observed to carry a balanced heterodicentric autosome (12 cases). However, among those, infertility was present in three cases 2 14 19 caused either by gonadal dysgenesis or severe oligospermia associated with abnormal sperm morphology. One other case was ascertained through recurrent spontaneous abortions. Four cases were found in skin cultures established from phenotypically normal induced abortuses. 15 Including two cases presented here, only four cases of non-Robertsonian heterodicentric autosomes were transmitted over two or more generations. Their heritability indicates their unique stability. In these cases there is a possibility of transmitting unbalanced gametes by non-disjunction as seen in case 2.
In the vast majority of cases (22/26) , the short arm of an acrocentric chromosome is involved in the translocation. A number of hypotheses can be advanced to explain the nonrandom participation of acrocentrics in the formation of non-Robertsonian heterodicentric chromosomes. There may be an increased rate of dicentric formation with acrocentrics based on non-random nuclear positioning of chromosomes. However, the latter explanation does not account for the randomness of the non-acrocentric chromosomes involved in the formation of the dicentrics. The predominance of acrocentics is probably more a reflection of the higher likelihood of stability of the dicentric formed. Deletion of the short arm of an acrocentric is often present, so the distance between the centromere of the acrocentric and the translocation breakpoint is always relatively small, which is in favour of dicentric stability. Moreover, absence of a phenotype related to a deletion of the p arm of an acrocentric is in favour of embryonic viability. It has been suggested by Roberts et al 12 that there may be a tendency for the centromeres of acrocentrics to become inactivated, making those dicentrics most likely to be stable and therefore visible in patients.
In the majority of cytogenetically recognisable heterodicentric autosomes, only one primary constriction is seen (14/18) in all cells of a given subject. The primary constriction corresponds to the activity of the centromere. 20 Even if this is a crude estimate, this suggests that only one centromere is active. Immunostaining against active centromere kinetochore specific protein (CENPs) is more reliable in assessing centromeric activity. Unfortunately, it was not possible to perform these studies in our cases. Earnshaw et al 21 have shown the presence of only one immunostaining signal against CENP-C on a dicentric chromosome consistent with the presence of one active centromere. The mechanism by which centromere inactivation occurs is still unknown. The primary constriction is found at the site of the non-acrocentric centromere in most instances (12/14) . Only two cases showed one primary constriction at the site of the acrocentric centromere. 8 18 Among non-Robertsonian heterodicentric autosomes, there were four cases of mosaicism for centromeric activity. 1 2 4 Intercentromeric distance seems to be one important factor in determining if a dicentric will be functionally dicentric or monocentric. 22 To be stable and lead to a viable embryo, dicentrics with distanced centromeres have to inactivate one centromere very soon after 
